Pathophysiological Role and Therapeutic Implications of Vitamin D in Autoimmunity: Focus on Chronic Autoimmune Diseases

Mattia Bellan 1,2,3, Laura Andreoli 4, Chiara Mele 1, Pier Paolo Sainaghi 1,2,3, Cristina Rigamonti 1,2,3, Silvia Piantoni 4, Carla De Benedittis 1,2,3, Gianluca Aimaretti 1, Mario Pirisi 1,2,3 and Paolo Marzullo 1,5,*

1 Department of Translational Medicine, Università del Piemonte Orientale UPO, 28100 Novara, Italy; mattia.bellan@med.unipr.it (M.B.); chiara.mele1989@gmail.com (C.M.);
pierpaolo.sainaghi@med.unipr.it (P.P.S.); cristina.rigamonti@med.unipr.it (C.R.); karla-89@hotmail.it (C.D.B.); gianluca.aimaretti@med.unipr.it (G.A.); mario.pirisi@med.unipr.it (M.P.)
2 Division of Internal Medicine, “AOU Maggiore della Carità”, 28100 Novara, Italy
3 CAAD, Centre for Autoimmune and Allergic Diseases, 28100 Novara, Italy
4 Rheumatology and Clinical Immunology Unit and Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, 25128 Brescia, Italy; laura.andreoli@unibs.it (L.A.); slv.piantoni@gmail.com (S.P.)
5 Division of General Medicine, Ospedale S. Giuseppe, I.R.C.C.S. Istituto Auxologico Italiano, 28921 Verbania, Italy
* Correspondence: paolo.marzullo@med.unipr.it; Tel. +390323514436

Received: 29 February 2020; Accepted: 13 March 2020; Published: 17 March 2020

Abstract: Vitamin D is a pleiotropic secosteroid yielding multiple actions in human physiology. Besides the canonical regulatory activity on bone metabolism, several non-classical actions have been described and the ability of vitamin D to partake in the regulation of the immune system is particularly interesting, though far stronger and convincing evidence has been collected in vitro as compared to in vivo studies. Whether vitamin D is able to regulate at physiological concentrations the human immune system remains unproven to date. Consequently, it is not established if vitamin D status is a factor involved in the pathogenesis of immune-mediated diseases and if cholecalciferol supplementation acts as an adjuvant for autoimmune diseases. The development of autoimmunity is a heterogeneous process, which may involve different organs and systems with a wide range of clinical implications. In the present paper, we reviewed the current evidences regarding vitamin D role in the pathogenesis and management of different autoimmune diseases.

Keywords: vitamin D; autoimmunity; autoimmune diseases; rheumatoid arthritis; spondyloarthritis; systemic lupus erythematosus; antiphospholipid syndrome; type 1 diabetes mellitus; autoimmune thyroid disease; Addison’s disease; autoimmune liver disease

1. Introduction

Vitamin D is a hormone, firstly characterized for its prominent role in bone homeostasis: in the early decades of the twentieth century, the discovery that rickets might be prevented and treated by sun exposure led to isolating and identifying vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol) [1]. In the following decades, our knowledge about vitamin D physiology grew significantly; indeed, vitamin D activity is integrated in a complex hormonal axis along with parathyroid hormone (PTH) and fibroblast growth factor 23 [2], such that cholecalciferol acts as
spare calcium at the level of the gut, the bone, the parathyroid glands and the kidney [3,4]. Besides the increasing awareness of the complexity of vitamin D activity on bone, the isolation of vitamin D receptor (VDR) in many different cell types made evident the wider role of this hormone in human physiology. Thus, more and more activities have been attributed to vitamin D: it contributes to the development of the nervous system, as well as to its protection, transmission, and plasticity [5]. Moreover, vitamin D exerts a protective role on the vascular endothelium [6–8], downregulates the renin-angiotensin-aldosterone system [9], and positively regulates insulin sensitivity [10], making vitamin D status a putative determinant of atherogenesis and a potential novel biomarker for cardiovascular risk [11]. Vitamin D status is also considered as a marker of general health, since low vitamin D levels are associated with cardio-metabolic disorders, neuromuscular disorders, cancer, and longevity [12].

Importantly, evidence has accumulated on the complex regulatory role of Vitamin D on the immune system, which is the result of its actions on both innate and adaptive immunity. Vitamin D contributes to hematopoiesis, since VDR drives the myeloid differentiation towards monocytes and granulocytes [13], and is involved in antimicrobial response, particularly against Mycobacteria infections. The exposure of human monocytes to such pathogens upregulates VDR expression. Further, the local activation of vitamin D is enhanced by the upregulation of the activating enzyme CYP27B1; a clinically relevant implication of this process is the increased risk of hypercalcemia which is observed in the context of granulomatous diseases, as a result of excessive local activation of cholecalciferol, which is released from the classical mechanisms of negative feedback [14].

The active form of vitamin D, 1,25(OH)2D3 (also called calcitriol) increases antimicrobial activity of macrophages and monocytes by enhancing the production of cathelicidin antimicrobial peptide (CAMP) and defensin β2 [15,16]. Moreover, 1,25(OH)2D3 induces chemotaxis and autophagy of innate immune cells [17,18] and upregulates their phagocytic activity, contributing to the clearance of pathogens [19]. In addition, vitamin D prevents infections by restricting the spreading of pathogens, via neutrophil extracellular traps (NETs) formation, as recently proposed [20]. A schematic illustration of 1α,25(OH)2D3 role in regulating the immune response is depicted in Figure 1.

![Figure 1. Scheme of 1α,25(OH)2D3 role in regulating immune response. As reviewed, it interacts both with innate- and adaptive-immune cells and with resident synoviocytes as well as osteoclasts, resulting in a decrease of synovial inflammation and, finally, in bone erosion.](image)

While on the one hand the active form of vitamin D promotes the antimicrobial activity of innate immunity, on the other it downregulates antigen presentation by monocytes, probably contributing to immune tolerance [21,22]. Additionally, 1,25(OH)2D3 drives monocytes differentiation towards macrophages [23] instead of dendritic cells (DCs) [24]. More generally, DCs...
activity is also impaired by 1,25(OH)2D3, which inhibits DCs chemotaxis and antigen presentation, by downregulating MHC II and costimulatory molecules expression [25,26].

The immunomodulatory effects of vitamin D on adaptive immunity are both indirect and direct. First of all, the spreading of adaptive response is negatively affected by the suppressive effect on antigen presentation. Moreover, vitamin D is able to downregulate the expression of proinflammatory cytokines by monocytes, such as Interleukin 6 (IL-6) and Tumor Necrosis Factor α (TNFα), which are part of the inflammatory milieu allowing B and T cells activation and proliferation [27].

VDR is expressed by B cells at low levels in quiescence and it is induced upon B cells activation [28]. The effects of 1,25(OH)2D3 on B cells are multiple: calcitriol induces B cells apoptosis, thus preventing proliferation and differentiation into plasma cells. By doing it, early administration of 1,25(OH)2D3 to stimulated B cells cultures reduces immunoglobulin secretion [29]. Furthermore, the in vitro activity of B cells as antigen presenting cells (APC) is inhibited by vitamin D, possibly through inhibition of the costimulatory signal mediated by CD86 [30].

T cells are another target of vitamin D action. 1,25(OH)2D3 inhibits the cytotoxic activity of T cells by suppressing the expression of Fas-ligand [31]. Vitamin D also has many effects on T helper cells (Th). Calcitriol drives CD4+ Th differentiation, leading to a reduction of Th1 and Th17 cells [32]. Th1 and Th17 subsets elicit a key role in different chronic inflammatory diseases, driving the inflammatory response by the release of cytokines. It is not surprising that the exposure to 1,25(OH)2D3 diminishes the expression of Th1 (IL-2, TNF-α, and Interferon γ- IFNγ) as well as of cytokines associated with Th17 (IL-17A, IL-17F, IL-21, IL-22) [33,34]. Conversely, 1,25(OH)2D3 polarizes CD4+ cells towards a Th2 phenotype with upregulation of cytokines such as IL-4 and IL-5 [35,36]. Finally, 1,25(OH)2D3 induces the differentiation of Treg, CD4+ cells involved in the maintenance of immune tolerance, by enhancing the expression of CTLA-4 and Foxp3. This in turn leads to an increase of IL-10 and transforming growth factor β [37,38].

In summary, there is strong evidence originating from studies showing that vitamin D is, at least in vitro, a regulator of multiple subsets of the immune system. However, the relevance of vitamin D-mediated regulation of the immune system in vivo is still to be proven. More specifically, it is unclear whether these potential beneficial effects are exerted at the plasma concentrations normally achieved in vivo or, conversely, if higher levels are required.

In this paper, our aim was to review the current evidences linking vitamin D to the regulation of immune system activity, specifically focusing on different autoimmune diseases.

2. Vitamin D and Inflammatory Arthritis

2.1. Rheumatoid Arthritis

Rheumatoid Arthritis (RA) is the most prevalent rheumatic chronic inflammatory disease worldwide; though characterized by the development of peripheral synovitis, it is considered a systemic disease linked to genetic and environmental factors. Looking at the effects that vitamin D plays on the immune system, different groups evaluated the potential pathogenetic relevance of vitamin D status on the development of RA. Moreover, despite the groundbreaking revolution caused by the introduction of biologics in the management of the disease, which dramatically improved its clinical and functional prognosis, there is still an ongoing search for novel drugs. In this context, vitamin D has some interest.

Since the late years of last century, different groups reported a potential protective and therapeutic effect of vitamin D on murine models of arthritis. The relevance of vitamin D in the pathogenesis of RA is supported by the observation that VDR-deficient mice are prone to a more severe arthritis when crossed with human TNF transgenic mice (hTNFtg), in comparison to VDR wild type/hTNFtg mice. VDR-deficient mice showed larger synovial infiltrates of inflammatory cells, and their monocytes demonstrated a pro-inflammatory phenotype, being particularly prone to differentiate into osteoclasts [39]. Tsuji et al., in 1994, reported that the oral administration of 1,25(OH)2D3 is able to protect mice from the development of collagen induced arthritis (CIA) caused
by the administration of type II collagen (CII) [40]. Similarly, the non-hypercalcemic analogue MC
1288 (20-epi-1α,25-dihydroxycholecalciferol) prevents CIA development when administered before
CII immunization; indeed, when started in mice with established CIA, MC 1288 is able to reduce the
severity of arthritis [41]. In a further model of RA (Adjuvant-induced arthritis, ATA), the effect of
vitamin D status on disease course was tested. Rats fed with a vitamin D-replete diet showed less
severe arthritis than those fed with a vitamin D deficient diet [42]. These observations suggest that,
in animal models, vitamin D signaling protects from arthritis and might be exploited for treatment.

Preclinical data suggest that 1,25(OH)2D3 can effectively regulate monocytes activity,
promoting an anti-inflammatory phenotype. When primary cultures of macrophages derived from
peripheral blood monocyte obtained from patients with RA are treated with 1,25(OH)2D3, TNF-α
and receptor activator of nuclear factor-κB ligand (RANKL) production dose-dependently decrease.
Moreover, at higher concentrations, 1,25(OH)2D3 also reduces the production of IL-1α, IL-1β, and
IL-6 [43]. In monocytes isolated from RA patients and stimulated with lipopolysaccharide (LPS), the
addition of 1,25(OH)2D3 and dexamethasone induces the development of a tolerogenic subset of
dendritic cells (tolDC), with a stable anti-inflammatory phenotype. These cells are able to suppress
the immunogenic activity of mature DC, inhibiting T cells proliferation and cytokines production
[44]; more specifically, tolDC suppress the development of Th17, and act simultaneously to
ameliorate the severity and progression of arthritis in a murine model [45]. In a recent study, DBA1/J
mice induced for CIA were treated intraperitoneally with 1,25(OH)2D3 which drove the CD4+
differentiation from a Th1-Th17 to a more favorable Treg phenotype. This was associated to
decreased incidence and lower clinical scores of arthritis, and reduced erosive burden [46].

Fibroblast-like synoviocytes (FLS) are another interesting target of vitamin D activity. These
cells are not mere innocent bystanders in RA; they actively participate in the inflammatory response,
specifically contributing to the development of bone erosions, one of the most important
pathogenetic moments in the course of the disease. 1,25(OH)2D3 acts on FLS isolated from RA
patients, significantly reducing the number of invasive FLS in vitro; this was associated to a
reduction of cytoskeleton reorganization and to a suppression of metalloproteinases (MMPs)
production [47]. Moreover, 1,25(OH)2D3 enhances FLS apoptosis preventing RA
[48,49]. In line with the previous findings, Wen et al. reported that 1,25(OH)2D3 is able to suppress
the IL-22 induced synthesis of RANKL by FLS; finally, 1,25(OH)2D3 inhibits the in vitro
osteoclastogenesis [50].

To summarize the currently available preclinical data, we can state that there is quite strong
evidence that the active form of vitamin D is able to prevent the development of murine models of
chronic arthritis; furthermore, it is promising as a therapeutic tool. In this setting, 1,25(OH)2D3
mainly drives immune response by acting on APC and creating a more tolerogenic and less
inflammatory phenotype and directly suppresses synovial proliferation and joint erosions.

However, how these convincing evidences translate to clinical practice is less clear. Should we
really postulate a potential protective role for vitamin D in vivo and, therefore, is hypovitaminosis D
a risk factor for RA? And again: can we really hypothesize for vitamin D a role in the treatment of
RA?

Concerning the first question, the literature is controversial. Hypovitaminosis D is undoubtedly
highly prevalent in patients affected by RA [51], however, as shown by a systematic review on this
topic, while some authors reported a statistically lower vitamin D plasma concentration in RA than
in the general population, this observation was not replicated by others [52]. We should always keep
in mind that what we measure to evaluate vitamin D status is 25(OH)D3 which is a more stable
intermediate metabolite, but which does not automatically reflect the real activity of vitamin D on
immune cells, being influenced by the degree of activation mediated by CYP27B1 and inactivation
mediated by CYP24A1. Furthermore, the immunological mechanisms triggering RA date back years
from disease onset; therefore, the evaluation of vitamin D status in a patient with an already
established disease is not informative for the potential protective role of this hormone on the
pathogenesis of RA. It is interesting to note that data from the Iowa Women’s Health Study (IWHS)
suggest a potential protective effect of higher vitamin D intake on incident RA in a very large
prospective cohort [53]. While it is unclear whether RA patients are more prone to hypovitaminosis D, there is convincing evidence that vitamin D status inversely correlates with disease activity when the disease is established [54,55].

It seems therefore reasonable to postulate a potential role for vitamin D for the treatment of RA [56,57]. We recently reviewed the current evidences supporting the use of cholecalciferol as a disease modifying antirheumatic drug in RA [58]. As discussed in the paper, the literature about this topic is controversial because of the small sample size of the interventional studies and their wide heterogeneity, both in terms of endpoints used to measure the outcome and supplementation regimens considered. Nevertheless, we managed to draw the following conclusions:

1. Hypovitaminosis D might contribute to the neuropathic pain, often present in RA [59]; the correction of vitamin D status, even with low doses aiming to normalize plasma levels, is convincingly effective in ameliorating pain [60];

2. The effect of cholecalciferol supplementation on disease activity is controversial; however, when vitamin D was used at higher doses, the supplementation regimen was generally beneficial [61,62]. This suggests that, possibly, the effect on immune system of vitamin D requires higher plasma levels than those necessary for bone health. Indeed, plasma 25(OH)D3 approximately doubles the synovial concentration [63]; the anti-inflammatory properties of this intermediate have been demonstrated at a 50-100 nM concentration. Thus, the plasma level required for bone health is probably ineffective to elicit immune regulation [37].

3. Vitamin D status correction is still to be considered quintessential for bone health, particularly in RA patients who are prone to bone loss, although the preferable regimen is not defined yet [64,65].

In conclusion, clinical studies are less convincing than preclinical data but, again, we should consider that the supplementation studies have been mainly conducted with an intermediate metabolite (cholecalciferol), which requires activation, while the in vitro studies have been performed with the active 1,25(OH)2D3. This might justify these discrepancies, at least in part.

2.2. Spondyloarthritis

Vitamin D status is generally poor in patients with spondyloarthritis (SpA) [66]. Despite the fact that vitamin D derivatives are topically employed in cutaneous psoriasis, its potential role in the pathogenesis and management of Psoriatic Arthritis (PsA) is less investigated than in RA. Different studies reported lower 25(OH)D3 plasma concentrations in PsA patients than in healthy controls [67], being vitamin D status inversely associated with inflammatory markers [68]. Data on effects of cholecalciferol supplementation on disease course are scarce. In 1990, Huckins and colleagues reported that the daily administration of calcitriol, in a small cohort of ten PsA patients, significantly improved tender joints count [69]. A further report belonging to 2009 showed the potential immunological effects of alphacalcidol administration, which was associated to a persistent improvement of disease activity [70]. Clearly, controlled trials are lacking and further studies are required to elucidate the potential therapeutic use of vitamin D in PsA.

In ankylosing spondylitis (AS) data are even less conclusive. The current evidences deriving from systematic reviews and meta-analysis suggest that AS patients harbor lower vitamin D values than controls [71,72]. However, whether an association links vitamin D status to disease activity is debated, with some papers demonstrating an inverse association between 25(OH)D3 and disease activity [73,74] and others refusing this finding [75,76]. Currently, there are no trials investigating the effect of vitamin D supplementation on disease activity.

3. Vitamin D and Autoimmune Connective Tissue Diseases

3.1. Systemic Lupus Erythematosus

Systemic lupus erythematosus (SLE) is a chronic multisystemic autoimmune disease characterized by tissue and organ inflammation and damage in relation to the production of autoantibodies directed against nuclear antigens.
In animal models of SLE, the relationship between vitamin D and disease manifestations is controversial, suggesting that the effect of vitamin D may be different depending on the target organ, explaining the clinical observation of different responses according to disease phenotype. In MRL/1 SLE mice, 25(OH)D3 reduced cutaneous lesions, proteinuria, and anti-double strand DNA (anti-dsDNA) autoantibodies [77], while cholecalciferol was associated with the worsening of histopathological damage in the NZB/W mice [78]. Recently, vitamin D supplementation in a rat model of SLE ameliorated their cognitive function by reducing the process of apoptosis in the hippocampus [79]. In a model of pristane-induced SLE in female BALB/c mice, supplementation with vitamin D improved arthritis, but not renal injury [80].

A reduction in anti-dsDNA production was observed when SLE-derived peripheral blood mononuclear cells were incubated with calcitriol [81]. In vitro, vitamin D reduced the state of activation of APC from SLE patients, inhibiting the expression of CD40, MHC class II, and CD86 molecules [82]. Likewise, treatment with vitamin D reduced the activation of DCs and the expression of genes related to IFN-alpha [83]. Vitamin D supplementation demonstrated a beneficial effect on B and T cell homeostasis derangement during the course of SLE as shown in two independent cohorts, by increasing Treg e Th2 [84] and decreasing Th17 and Th1 cells, and memory B cells [85].

Vitamin D deficiency has been observed to be associated with SLE disease expression, relapses, and pathogenesis [86,87]. Systematic reviews and meta-analyses have been published on the significance of lower circulating levels of vitamin D in patients with SLE of different ethnicity when compared to healthy controls [88–90]. In particular, vitamin D status inadequacy was more prevalent among unsupplemented SLE patients living at a latitude beyond the 37° parallel north and [88]. The reduced sun exposure due to photosensitivity and the use of photo-protection, as well as the alteration of its renal metabolism, the presence of VDR polymorphisms which reduce the cell responsiveness to the hormone or the genetic variants of two genes encoding key enzyme regulators of endogenous production, were all described as additional risk factors for vitamin D insufficiency in SLE patients as compared to healthy controls [91,92]. Medications used for the treatment of SLE may also influence the vitamin D status. Data on hydroxychloroquine (HCQ) are still controversial: some authors found lower vitamin D levels in patients treated with HCQ [93], although others found opposite results or did not observe any association [94,95]. Noticeably, chronic corticosteroid use reduces intestinal absorption and accelerates the catabolism of 25(OH)D3 and 1,25(OH)2D3 through an increase in CYP24A1 activity [96,97].

Active SLE patients with lupus nephritis harbored significantly lower vitamin D levels than their counterparts [98]. Furthermore, vitamin D exerts a protective role in podocyte injury induced by autoantibodies from patients with nephritis [99]. Lower vitamin D levels in the bloodstream appear to be associated with worse disease activity, as well as with extra-musculoskeletal complications such as fatigue [100], cardiovascular risk [101], and cognitive impairment [102,103]. In addition, a recent longitudinal cohort analysis showed that vitamin D deficiency was associated with more active disease at baseline and over time, as well as a trend toward more severe lupus flares [104].

Despite the debate about low levels of vitamin D being either the cause or the consequence of SLE [105], vitamin D supplementation should be deemed as integral part of SLE management strategies [88].

Concerning the relationship between vitamin D supplementation and SLE disease activity, two RCTs [106,107], one open clinical trial [108] and a cohort study [109] found that vitamin D supplementation is able to reduce disease SLE activity, while two cohort studies [110,111] and a RCT [112] failed to observe any significant variation. Schedules and dosages were highly variable across these studies. SLE serology does not seem to be affected by vitamin D supplementation given both with an intensive or a standard regimen [110], while a higher vitamin D dose was able to reduce anti-dsDNA antibodies [85]. Some authors demonstrated that vitamin D supplementation may play a role in decreasing urine protein-to-creatinine ratio and the likelihood of clinical proteinuria [109]. Table 1 reports the major finding of prospective studies of vitamin D supplementation in SLE patients.
| Author                  | Type of Study                  | Number of Enrolled Patients | Type of Supplementation                                                                 | Main Findings                                                                                                                                                                                                 |
|------------------------|--------------------------------|----------------------------|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Ruiz Irastorza et al.  | Longitudinal observational    | 80                         | Cholecalciferol, 600-800 IU day p.o. (24 mos)                                              | Improved fatigue symptoms, no correlation with SLEDAI or SDI. Side effects: not reported                                                                                                                    |
| Terrier et al.         | Prospective                    | 20                         | Cholecalciferol, 100.000 IU/wk p.o. (4 wks)                                               | Improved naïve CD4+ T cells, regulatory T cells; reduced Th1 and Th17 cells, memory B cells, anti-DNA antibodies. No cases of hypercalcemia                                                                 |
| Petri et al.           | Prospective                    | 1006                       | Ergocalciferol, 50.000 IU/wk p.o., calcium/vitamin D 200 IU/twice daily p.o.               | Reduced SELENA-SLEDAI, decreased urine protein-to-creatine ratio. Hypercalcemia rate, 0.002%                                                                                                               |
| Andreoli et al.        | Prospective, cross-over        | 34                         | Cholecalciferol Intensive Regimen: 300.000 IU bolus plus 50.000 IU/mo p.o. (850.000 IU/yr). Standard Regimen: 25.000 IU/mo p.o. (300.000 IU/yr) for 12 mos. Regimens switched in the second year. Cholecalciferol Intensive Regimen: 300.000 IU bolus plus 50.000 IU/mo p.o. (850.000 IU/yr). Standard Regimen: 25.000 IU/mo p.o. (300.000 IU/yr) for 12 mos. Regimens switched in the second year. | No effect on disease activity and SLE serology. No cases of hypercalcemia. Slight transient hypercalciuria in 3 mos.                                                                 |
| Piantoni et al.        | Prospective, cross-over        | 34                         | Cholecalciferol, 50.000 IU/wk p.o.                                                       | Enhancement of T-reg cells and Th2 cytokines. No cases of hypercalcemia                                                                                                                                    |
| Aranow et al.          | Randomized, double blind, placebo controlled | 57                         | Cholecalciferol, 2.000 or 4.000 IU/d p.o.                                                  | Well-tolerated. No effect on IFN-alpha. No cases of hypercalcemia                                                                                                                                     |
| Lima et al.            | Randomized, double blind, placebo controlled | 40 (JoSLE)                    | Cholecalciferol, 5000 IU/wk p.o.                                                         | Decreased disease activity and improved fatigue symptoms in JoSLE patients. No cases of hypercalcemia                                                                                                 |
| Rifa’i et al.          | Randomized, placebo controlled | 39                         | Cholecalciferol, 1.200 IU/d p.o.                                                         | Decreased SLE disease activity and fatigue symptoms. Side effects: not reported                                                                                                                        |
| Karimzadeh et al.      | Randomized, double blind, placebo controlled | 90                         | Cholecalciferol, 50.000 IU/wk p.o. for 12 wks and 50.000 IU/mo p.o. for 6 mos.             | No effect on SLE disease activity. Side effects: not reported                                                                                                                                        |
Assessment of safety: including hypercalcemia, hyperphosphatemia or lithiasis; JoSLE: juvenile-onset SLE; IFN-alpha: alpha interferon; SLEDAI: systemic lupus erythematosus disease activity index, SDI: rheumatology damage index.
Osteoporosis and fractures greatly contribute to bone damage in SLE patients, symptomatic fractures being reported in 6–42% of patients following SLE diagnosis [113]. Vitamin D deficiency is considered as a major risk factor for bone damage along with persistent activity of disease, use of glucocorticoids, kidney disorders, premature menopause, and physical inactivity that is due to chronic pain and fatigue. Vitamin D supplementation is indicated for both prevention and treatment of osteoporosis in SLE patients at the daily oral dose of 800–2000 UI of cholecalciferol so as to maintain serum vitamin D levels above the target of 30 ng/ml [114]. Of note, cardiovascular events are the major comorbidities in SLE patients being accelerated atherosclerosis responsible for their premature cardiovascular diseases [115], and a recent study suggested vitamin D and calcium supplementation may have effects on the arterial stiffness of SLE patients. Longitudinal studies are indeed warranted on larger affected populations with longer follow-ups [116].

Interventional studies also pinpointed the relevance of vitamin D supplementation safety. Vitamin D toxicity is possible, although rare, and the main complications are hypercalcemia and hypercalciuria. Globally, the dosages used in these studies appeared to be safe and none of these studies described an increased occurrence of lithiasis.

In conclusion, vitamin D supplementation is strongly recommended in SLE patients. Firstly, for the prevention of glucocorticoid induced osteoporosis, but also for possible immunomodulatory effects that remain to be fully elucidated [117]. Current vitamin D supplementation strategies are not sufficient in rising serum levels of vitamin D in every patient, therefore a treat-to-target approach could be a possible solution. For this reason, an initial measurement of serum levels of vitamin D should be done for each patient. As a general rule, 100 IU/day of vitamin D intake is needed to increase 1 ng/ml of serum 25(OH)D, which takes about 3 months to became stable once supplementation is started [118].

3.2. Antiphospholipid Syndrome

The antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by thrombotic manifestations and/or pregnancy-related complications in patients with confirmed antiphospholipid antibodies (aPL). Lower vitamin D levels have been described in APS patients when compared to healthy controls [119–121], particularly in patients with thrombotic disease [122]. However, no stringent lifestyle recommendations or dietary restrictions have been expressed for patients with APS with reference with vitamin D deficiency [123]. Studies in vitro showed that, in monocytes stimulated by anti-b2glycoprotein I (anti-b2GPI) antibodies derived from APS patients, vitamin D can inhibit the expression of tissue factor [124]. The relationship between vitamin D and thrombosis has been further investigated [125,126], as VDR activators can intervene to control the expression of several thrombogenic factors [127]. Nevertheless, 25(OH)D3 supplementation in obese women failed to improve haemostatic parameters as assessed by calibrated automated thrombogram [128]. Vitamin D deficiency was found as a risk factor also for recurrent pregnancy losses in patients with aPL, in association with other signs of autoimmunity [129]. In early pregnancy, vitamin D is produced by trophoblasts contributing to decidualization for successful pregnancy [130,131]. According to the EULAR recommendations, supplementation with calcium, vitamin D, and folic acid should be offered to patients with APS (and/or SLE), particularly in the case of vitamin D deficiency in the first trimester of gestation and in patients receiving glucocorticoids and/or heparin for their detrimental effects on bone mass [132].

4. Vitamin D and Autoimmune Endocrine Diseases

4.1. Type 1 Diabetes Mellitus

Type 1 diabetes (T1DM) is an autoimmune disease characterized by an immune-mediated destruction of pancreatic beta-cells, which leads to a lifetime dependence on exogenous insulin [133,134]. The causes of T1DM onset are incompletely defined and a combined effect of genetic predisposition and environmental triggers has been hypothesized [135,136]. It is estimated that 542,000 children aged under 14 years are affected by T1DM, with an incidence that has increased by
3–4% over the last thirty years [137]. The pathogenetic role of vitamin D in T1DM onset is debated. The Type 1 Diabetes Genetic Consortium, which genotypically characterized 38 single nucleotide polymorphisms (SNPs) in more than 1500 families with T1DM, did not observe correlations between SNPs in the VDR and T1DM [138], even if associations between some VDR polymorphisms (BsmI, FokI, TaqI, ApaI) and T1DM have been pinpointed in several population studies [139–148]. In 2017, Sahin OA et al. [149] published a meta-analysis, with the aim to evaluate the relationship between ApaI, BsmI, FokI, and TaqI polymorphisms of VDR and T1DM in children. The authors analyzed 9 studies, including a total of 2070 patients and controls. Their results showed that BsmIbb, BsmIIBB, and TaqITT polymorphisms were linked to a higher risk of T1DM onset, whilst BsmIlbb and TaqITT seem to play a protective role [149].

In preclinical studies, an intriguing role for vitamin D in the pathogenesis of T1DM has been postulated. Vitamin D prevents β-cell apoptosis caused by cytokine exposure and restores insulin secretion [150]. In vitro and animal studies suggested that vitamin D could exert a modulatory effect on the immune system by showing that supplementary treatment with vitamin D may have a protective role against the T1DM onset in experimental models [151]. In humans, the prevalence of T1DM is associated with ultraviolet B radiation, altitude and latitude as well as it displays a seasonal pattern, suggesting a pathogenetic role for vitamin D in this context [152–154]. Moreover, lack of vitamin D supplementary treatment in childhood and lower maternal 25(OH)D3 plasma levels during pregnancy could be related to an increased risk of T1DM onset later in life [155,156]. Furthermore, a meta-analysis including five observational studies reported that vitamin D supplementary treatment during infancy is associated with a lower risk of T1DM [151]. Finally, other studies and meta-analyses demonstrated that patients with T1DM harbor lower serum levels of vitamin D compared to controls and showed how vitamin D deficiency could be associated with a worse glycaemic control [157–165]. However, two large population-based Danish studies did not observe any association between vitamin D concentrations and later risk of developing T1DM [166], while other studies did not find significant differences in vitamin D levels between patients with T1DM and controls [167–169].

The results of interventional studies are also conflicting. An open-label randomized trial on 70 T1DM patients, treated with low dose of calcitriol or nicotinamide for one year, did not observe differences in C-peptide or HbA1c levels, while a modest effect of calcitriol on the residual pancreatic beta-cell function was observed [170]. In 2013, Papadimitriou et al. demonstrated that 0.25 μg/day of calcitriol administered to 12 high-risk children with T1DM was able to abolish the presence for anti-GAD65 antibodies and insulin autoantibodies after 6 months [171]. Moreover, the supplementary treatment with calcitriol in subjects with latent autoimmune diabetes in adults (LADA) seems to exert a protective effect on residual pancreatic beta-cell function compared with patients treated only with insulin analogue [172]. On the contrary, Walter et al. observed that 0.25 mg per day of calcitriol did not seem to preserve beta-cell function [173]. According to a later systematic review of 7 randomized controlled clinical trials, supplementary treatment with vitamin D, in particular with alpha-calcidol and cholecalciferol, might attenuate the natural course of the T1DM [174]. Finally, vitamin D supplementation seems to reduce glycaemic variability, insulin requirements and hypoglycaemia rates [175].

In conclusion, these data suggest that an adequate supplementary treatment with vitamin D could be able to improve glycemic control in T1DM patients and to prevent the disease onset in high risk subjects.

4.2. Thyroid Autoimmunity

Autoimmune thyroid disorders (AITD) are the most common autoimmune diseases with a prevalence of 5% in the general population and an increasing trend in the incidence over the years [176]. The aetiology of AITD is multifactorial, involving genetic predisposition and environmental factors [177]. Hashimoto’s thyroiditis (HT), and Graves’ disease (GD) represent the most frequent AITD, immunologically characterized by circulating antithyroid antibodies and thyroid glandular infiltration of lymphocytes, respectively [178].
Several preclinical and clinical studies observed a relationship between hypovitaminosis D and AITD [179,180]. Figure 2 illustrates the main pathophysiological correlates of vitamin D effects on AITD.

Figure 2. Hashimoto’s thyroiditis (HT) is a T-cell-mediated endocrine autoimmune disease. Patients harbor higher thyroid peroxidase antibodies (TPOAb) and TgAb serum levels and thyroid intraglandular infiltration of B and T lymphocytes with CD4+ Th1 subtype predominance. Graves’ disease (GD) is characterized by a prominent Th2-mediated humoral response, which induce the expression of stimulatory antibodies. Vitamin D is able to reduce the proliferation and differentiation of B cells into plasma cells and induce the apoptotic cascade of immunoglobulin. In this context, vitamin D inhibits the Th1 cells proliferation as well as the Th1-mediated cytokines production (IL-2, IFN-γ, and TNFα) and modulates Th2 cells and cytokines production (IL-4, IL-5, and IL-10) inducing Th2 phenotype. Arrows are used to illustrate decreased (↓) or increased (↑) production of specific molecules.

In a 1990 study based on evidence that in vitro inhibition by cyclosporin A (CsA) is potentiated by calcitriol, Fournier et al. investigated in vivo the influence of both molecules by using an experimental mouse model of AITD [181]. The study demonstrated a synergistic role of calcitriol in reducing the incidence of thyroid autoimmunity and the severity of histological lesions. Several years later, Borgogni et al. investigated the effects of elocalcitol, compared with methimazole, on CXCL10 secretion induced by proinflammatory cytokines in human thyrocytes. Their results showed that elocalcitol inhibited IFN-γ and TNFα-induced CXCL10 protein secretion more effectively than methimazole and promoted a shift toward a Th2 response [182].

Animal models deploying an immunization protocol with thyroid stimulating hormone receptor antibody (TSHR Ab) showed that vitamin D deficiency promoted persistent hyperthyroidism, leading to speculate on a potential modulatory effect of vitamin D on thyroid function [183]. One year later, Liu S et al. analyzed the effect of calcitriol on thyroid inflammation and Th1/Th2 cells in mice with experimental autoimmune thyroiditis [184]. The authors demonstrated that calcitriol can help to maintain normal autoantibodies and citokines levels as well as the thyroid glandular structure when administered before the onset of the experimental damage.

The mechanisms behind the putative beneficial effects of vitamin D on AITD mentioned above are unclear, but they are possibly related to its known immunomodulatory and anti-inflammatory properties.

Hashimoto’s thyroiditis (HT) is often characterized by hypothyroidism and the production of thyroid autoantibodies like thyroid peroxidase antibodies (TPOAb) and thyroglobulin antibodies (TgAb), and with thyroid glandular lymphocytic infiltration [185].

Several observational and interventional studies found a potential link between hypovitaminosis D and a higher risk of HT onset. The first observational study was published by
Goswami et al. in 2009 and observed an inverse correlation between serum vitamin D levels and TPOAb titres [186]. Later, studies confirmed this negative association [187–192] and also reported a negative correlation between vitamin D and TgAb serum concentrations [189,191]. Several studies demonstrated that TPOAb positivity was more frequent in subjects with hypovitaminosis D compared to subjects with sufficient hormone levels [187,193–199]. Further studies also demonstrated an association between the VDR polymorphisms and a higher incidence of HT, particularly VDR rs731236, rs1544410, and rs2228570 [200].

Human intervention studies demonstrated that cholecalciferol supplementation was associated with an important decrease in TPOAb and TgAb levels both in patients with vitamin D sufficiency and deficiency [201–204]. In a recent 3-month RCT on women with HT, Chahardoli R et al. not only observed a significant decrease of TgAb after cholecalciferol supplementation (50,000 U), but also reported a significant reduction of TSH levels [205].

Graves’ disease (GD) is a common autoimmune disease with an incidence of 14/100,000 per year and is characterized by the presence of thyroid stimulating hormone (TSH) receptor autoantibodies which cause hyperthyroidism, goiter, and ophthalmopathy [206,207]. Although some studies observed an increased prevalence of GD in subjects with hypovitaminosis D, the association between these two conditions is not so straightforward [208]. The first observational study on this topic examined vitamin D levels in female population with and without remission of GD [209]. The authors found higher vitamin D in GD women with remission as compared to those without. One year later, Unal et al. showed that patients with GD harbor lower vitamin D levels than normal controls [189]. These results have been further confirmed by three recent observational studies [197,210,211]. Moreover, Xu and colleagues conducted a meta-analysis with 26 clinical studies, showing that hypovitaminosis D seems to double the risk of GD onset [212]. Recently, an interventional study was designed to evaluate whether daily supplementary treatment with vitamin D reduces GD recurrence. The results showed that GD recurrence occurred earlier in patients not receiving vitamin D supplementation [213]. Finally, as in the case of HT, polymorphisms of VDR gene seem to be related to a higher risk of GD occurrence in several investigations, but with a low statistical power [214].

Summarizing, studies observed a correlation between hypovitaminosis D and thyroid autoimmune diseases. Cholecalciferol supplementation seems to exert beneficial effects on thyroid autoimmunity. However, large multicenter studies are needed to determine the impact of supplementary treatment with vitamin D on clinical outcomes in AITD.

4.3. Addison’s Disease

Addison’s disease (AD) represents a rare adrenal autoimmune disease characterized by a current prevalence of 100–140 cases per million population [215]. A steady increase of the prevalence of AD has been observed over the years, particularly in women [216]. AD clinically occurs with adrenal insufficiency, caused by an autoimmune-mediated destruction of adrenal cortex [217]. Although the pathogenesis of AD has not been completely elucidated, an interplay role between HLA haplotypes and environmental factors has been postulated [218,219]. In addition, different genes responsible for vitamin D metabolism and VDR gene polymorphisms are implicated in AD onset [220–223]. Only few studies evaluated the potential relationship between AD and circulating vitamin D levels. In 2013, Ramagopalan and colleagues investigated the potential role of hypovitaminosis D in influencing the pathogenesis of immune-mediated diseases [224]. The authors observed that in patients with hypovitaminosis D there were significantly higher rates of AD and other autoimmune diseases. Subsequently, Pazderska et al. demonstrated that subjects born in the winter had a higher risk of AD occurrence [225]. These results suggested that hypovitaminosis D, coupled with exposure to seasonal viral infections, could deregulate the innate immunity increasing the risk of AD onset [225]. In 2018, Penna-Martinez and colleagues conducted a pilot trial to investigate the effects on the immune response of patients with AD of high dose cholecalciferol therapy (4000 IU/day) over a 3-month period. The authors observed that supplementation with
cholecalciferol could interfere with the late activation of monocytes and T-cells in subjects with AD, providing novel insights about immunomodulation in AD [226].

It may thus be concluded that only preliminary evidence exists to suggest that hypovitaminosis D and AD could be closely related, considering the potential role of vitamin D in modulating the immune response.

4.4. Autoimmune Polyendocrine Syndromes

Autoimmune polyendocrine syndromes (APS) represent rare conditions characterized by autoimmune activity against multiple endocrine organs [227]. The two major APS, APS-1 (AD, hypoparathyroidism and candidiasis), and APS-2 (AD, AITD and T1DM), have Addison’s disease as a prominent component. APSs include APS-3 (AITD and other autoimmune diseases) and APS-4 (autoimmune polyendocrinopathies that do not fulfill the criteria of APS 1 to 3) [228]. Across different countries, the estimated prevalence of APS is reportedly around 1:80,000 [229]. To date, only a single clinical study evaluated the potential association between circulating vitamin D levels and APS. The authors observed that subjects with APS showed lower 25-OHD serum concentrations compared to healthy controls [230]. It is currently unclear if hypovitaminosis D could represent a cause of APS onset rather than a consequence.

5. Vitamin D and Autoimmune Liver Diseases

Autoimmune liver diseases, despite being relatively rare, represent a relevant cause of liver-related morbidity and mortality. Autoimmune hepatitis (AIH) is an immune-mediated chronic liver disease with no defined cause, accounting for about 16–18 cases per 100,000 inhabitants in Europe. The main target of auto-inflammation are primarily hepatocytes. AIH can range from a mild, asymptomatic disease to a severe form of acute or even fulminant hepatitis and appears to be more frequent in women, although its incidence among men is on the rise [231].

Cholestatic autoimmune liver diseases include primary biliary cholangitis (PBC), which is a chronic small bile duct cholangitis affecting about 1 in 1000 women aged over 40 worldwide and presents with non-suppurative granulomas [232,233], and primary sclerosing cholangitis (PSC), affecting mainly young men with both small and large bile ducts involvement [234]. Although the complex pathogenesis of autoimmune liver diseases is still incompletely understood, it has been hypothesized a role for vitamin in this setting. Many studies have investigated the influence of 1,25(OH)2D3 in the liver. It is known that it directly influences cytoplasmic calcium levels in rat hepatocytes [235] and promotes liver regeneration after hepatectomy in murine models [236]. It has been found that vitamin D increases the expression of P450 cytochromes (CYP3A4, CYP2D6, CYP2C9) in human primary cultured hepatocytes [237]. In addition, it has been reported that the isoenzyme CYP2D6 could potentially convert vitamin D3 into 25-hydroxy-vitamin D [238]. CYPs are common targets of immune-mediated reactions in autoimmune liver diseases. In particular, CYP2D6 expressed on the membrane of hepatocytes is the major auto-antigen for anti-liver kidney microsome type 1 (LKM1) antibodies in type 2 AIH [239]. The clinical relevance of anti-CYP2D6 auto-reactivity in autoimmune hepatitis is supported by animal models: mice infection with CYP2D6-expressing Ad5 adenovirus leads to the production of anti-CYP2D6 IgG that cause immune-mediated liver injury by recognizing the same epitopes targeted by human auto-antibodies [240].

There are several potential implications of vitamin D in AIH, due to both genomic and non-genomic functions, such as suppression of MHC-II antigen expression and increase of CTLA-4 production [241]. As shown in a model of Concanavalin A (Con-A) induced autoimmune hepatitis in mice [242], calcitriol decreases serum ALT levels, attenuates histological liver damage, and decreases IFN-γ levels.

The liver immunomodulatory effect of vitamin D appears to be related to the 25-hydroxylation, which creates a negative feedback for local inflammation and leads to Th2 polarization [243], due to the inhibition of pro-inflammatory TNF-α, IL-2, IL-12, IL-17, IFN-γ, and promotion of IL-4, IL-5, and IL-10 production [244]. In addition, calcitriol may exert an anti-oxidant by increasing intracellular
glutathione and counteracting reactive oxygen species, which have been suggested to be involved in AIH and PBC. In fact, a vitamin-D poor diet has been shown to increase NADPH in rat hepatocytes [245]. Moreover, a putative immunomodulatory role of vitamin D seems to be linked to its influence in hepatic invariant natural killer T-lymphocytes (iNKT) development. These are mostly found in hepatic sinusoids and are able to activate hepatic stellate cells, as well as to mediate hepatocytes' killing [246]. Liver iNKT cells constitutively express OX40, which is involved in inducing proinflammatory and profibrotic liver injury, as reported by Lan and colleagues [247]. Although iNKT role in autoimmune liver disease is still not fully understood, it has been reported that these activated cells mediate a major role in inflammation and hepatocyte death in a murine model of Con-A-induced autoimmune hepatitis [248].

In this setting, animal models have shown that adequate levels of vitamin D are essential for normal iNKT development. It seems that vitamin D accounts for the number of iNKT cells, whereas the VDR plays a role for both iNKT number and function [249]. Interaction of vitamin D with its receptor VDR results in many effects other than its role in T cell differentiation. This receptor is expressed by CD4+ T lymphocytes, CD8+ T lymphocytes, B lymphocytes, DCs, NK cells and macrophages [250]. VDR receptor is widely expressed at low levels within hepatocytes, whereas high levels of VDR expression have been demonstrated in hepatic non parenchymal cells, such as biliary epithelial cells and hepatic stellate cells (HSCs) [251]. VDR-mediated signaling in HSCs seems to act by antagonizing the potent hepatic profibrogenic TGF-β/SMAD-dependent transcriptional pathway [252].

The locally produced 1,25(OH)2D3 is also responsible for a negative feedback for the expression of VDR in bile duct cells [243]. VDR could be involved in maintaining bile duct integrity, suggesting a potential involvement in cholestatic liver damage. Ferrinči et al. found that VDR knockout mice presented an impairment in bile acid homeostasis, ductal reaction, as well as disruptions in biliary epithelial junctions following a biliary-type liver injury [253]. Moreover, the signaling activated by vitamin D-VDR interaction can modulate the transcriptional response related to bile acid resulting in a putative protection of hepatocytes from cholestatic injuries [254].

An additional anti-inflammatory action of 1,25(OH) is related to the fact that it increases the activity of MPK-1, consequently inactivating the mitogen-activated protein kinases (MAPKs); the subsequent modulation of nuclear factor of activated T-cells (NFAT), NF-κB, and nuclear histone deacetylase, reduces inflammatory activity in immune-mediated diseases [244].

Vitamin D also increases the glucocorticoid anti-inflammatory function by stimulating the synthesis of mediator complex subunit 14 (MED14); it induces the binding of the activated glucocorticoid receptor to the glucocorticoid-responsive element in the MPK-1 gene promoter. In addition, 1,25(OH)2D3 emphasizes the negative effect of glucocorticoids on the production of LPS-induced IL-6 [255] and interferes with the translocation of NF-κB to the nucleus [256]. As glucocorticoids are the main therapeutic agents used for autoimmune hepatitis, this finding might have potentially therapeutic implications for a putative role of vitamin D supplementation to booster steroidal treatment efficacy.

Calcitriol has antifibrotic and anti-proliferative effect on the liver, as shown both in in vitro and in vivo models [257]. Liver damage and inflammation frequently result in hepatic fibrosis. Pro-inflammatory cytokines activate HSCs, which transform into myofibroblasts with consequent proliferation, contractility, loss of intracellular retinoid stores, cytokine production, and extracellular matrix deposition [258]. It has resulted that 1,25(OH)2D3 inhibits proliferation, activation, and transformation of HSCs into myofibroblasts in a murine model of liver injury induced by thioacetamide [259].

Emerging evidence suggests that vitamin D could protect against liver fibrogenesis, due to different mechanisms. One of the most important is the signaling mediated by VDR [257] which, as discussed before, is extensively expressed on HSCs: Ding et al. showed that VDR knockout mice develop spontaneous liver fibrosis [252], because of an impairment in VDR/SMAD genomic feedback.
It has been shown that 1,25(OH)2D3 decreased the mRNA transcription for type I collagen in cultured human HSCs by interacting with VDR [260]. Vitamin D, besides repressing collagen I and III expression, strengthens the expression of matrix metalloproteinase-8 (MMP-8), a collagen cleaving enzyme [261].

Moreover, activated HSCs secrete connective tissue growth factor (CTGF) as well as other matricellular proteins [262]. In a rat model, a significant reduction of CTGF expression has been observed after vitamin D treatment [263]. Similar results were obtained by evaluating the correlation between circulating levels of CTGF and severity of liver fibrosis in a cohort of patients with biliary atresia [264].

Supplementation of vitamin D may prevent liver fibrosis development, as resulted in murine models of primary sclerosing cholangitis [265] and thioacetamide-induced cirrhosis [259].

It is widely reported the higher frequency of vitamin D insufficiency or deficiency among autoimmune liver diseases patients compared to healthy subject. Scarcity of vitamin D has been evaluated as a prognostic marker, linked to disease severity [266–268]. Serum levels of 1,25(OH)2D3 lower than 20 ng/mL have been described in a large proportion of patients with non-cholestatic autoimmune liver diseases (51–92%), and vitamin D insufficiency has been reported in 17–23% of patients [244].

There are several studies focusing on the potential relation of low vitamin D level and chronic liver disease, irrespective of the cause, as reviewed by Chen et al. [243]. Stokes et al. have found low vitamin D concentration to be independent predictor of mortality in cirrhotic patients (OR 6.3; 95% CI 1.2–31.2, P = 0.012): they also reported an inverse correlation between serum levels of vitamin D and the stage of cirrhosis (Child–Pugh score and model of end-stage liver disease–MELD score), mainly associated with liver failure and infections [269]. Despite that vitamin D deficiency has not resulted as a predictor of poor prognosis in AIH by itself, it has been proposed as a biomarker with potential prognostic role in this setting, as it resulted associated to more severe interface hepatitis and worse fibrosis scores; the lower the vitamin D levels, the higher appeared to be the rate of a poor response to treatment [270]. Comparable results were found by Ebadi et al. [266].

Moreover, it has been reported that 25(OH)D3 level increases in patients with AIH who are responsive to classic steroid therapy, while it does not rise in non-responders [270].

A potential prognostic value of vitamin D levels has also been described in PBC. Agmon-Levin et al., in fact, have shown that vitamin D levels resulted significantly reduced among PBC patients compared to controls, and they correlated to higher alkaline phosphatase levels as well as advanced liver damage. Patients treated with ursodeoxycholic acid (UDCA) have been described to have higher vitamin D levels [267].

It has also been postulated that pre-treatment vitamin D level could be independently associated to subsequent UDCA response [271].

Regarding VDR, it has been described an association between autoimmune liver diseases and VDR polymorphisms: in particular, Vogel et al. found out that FokI polymorphism associated to AIH, whereas BsmI polymorphism was increased in PBC affected patients in a German population [272]. The same result has been shown in a Chinese population [273] and in a Canadian group of PBC patients, in which has been postulated that VDR polymorphisms could be an independent risk factor for a lower bone mineral density [274]. These findings suggest a putative involvement of these polymorphisms with regard to D-mediated immunomodulation, although the mechanisms remain unknown.

The implication of vitamin D-VDR signaling pathway has been studied in the PBC and PSC pathogenic process. Kempinska-Podorodecka et al. found that in PBC livers, either cirrhotic or not, there is a significant impairment in VDR expression, resulting in enhancement of non-coding miR155 and consequent SOCS1 reduction, which probably interferes with the negative feedback on pro-inflammatory cytokines response [275]. Actually, VDR is also an important receptor for ursodeoxycholic acid (UDCA) inducing cathelicidin expression in biliary epithelial cells [243]; it also mediates many epigenetic effects, which contribute to the reduction of pro-inflammatory cytokines synthesis [276].
It should also be taken into consideration that low serum concentration of vitamin D in chronic liver disease patients might reflect a deficiency in hepatic hydroxylation due to impaired liver function [277]. The lack of proper hydroxylation may be a consequence of liver disease, but it cannot be excluded that it may pre-exist liver disease, playing a role in its pathogenesis and progression [244].

Based on what was previously discussed, we can hypothesize that 1,25(OH)2D3 may be used as a potential prognostic biomarker of disease severity and treatment response [270].

The putative therapeutic benefit provided by vitamin D supplementation in chronic liver diseases needs further study to be confirmed. A recent systematic review published in 2017 [278], including 15 trials and 1034 patients in total, concluded that no strong evidence has been found supporting the hypothesis that vitamin D supplementation confers an advantage in this setting, though none of the trials included patients with autoimmune liver disease. However, considering the synergistic cooperation of vitamin D and glucocorticoids in suppressing inflammation, it would be interesting to conduct a prospective investigation to determine whether correction of vitamin D deficiency could strengthen the effect of corticosteroids or contribute to dose reduction and individualization.

Summarizing, vitamin D, along with its relative VDR is possibly inter-related with the occurrence, treatment, and prognosis of autoimmune liver diseases and represents an interesting and intriguing topic to further explore in order to improve prevention and management of immune-mediated liver diseases.

6. Conclusions

Knowledge on the role of vitamin D in the control of bone health physiology has been progressively integrated by evidence that vitamin D yields pleiotropic “non-calcemic” effects in vitro and in vivo, potentially linking vitamin D status with general health. A main extra-skeletal effect of vitamin D activity is related to the immune system homeostasis. Hence, a disturbed vitamin D-VDR axis is potentially viewed as a trigger for a wide spectrum of autoimmune diseases, such as inflammatory arthritis, connective tissue diseases, endocrinopathies, and different categories of autoimmune liver diseases. In vitro and in vivo data support this link and demonstrate that, at least in experimental conditions, the modulation of vitamin D of innate and adaptive immunity can contribute to prevent the susceptibility to autoimmune diseases and improve their therapeutic management.

Unfortunately, studies cannot exclude reverse causality, i.e., that low levels of vitamin D may derive from impaired kinesis or avoidance of sunlight in people with autoimmune diseases. For these reasons, randomized controlled trials are needed on treatment with vitamin D in patients with or at risk for autoimmune diseases, so as to heighten data and accuracy on the information available on vitamin D efficiency in the clinical setting of autoimmune disorders.

Author Contributions: Conceptualization and methodology, M.B., L.A., P.M.; original draft preparation, M.B., L.A., C.M., P.P.S., C.R., S.P., C.D.B., P.M.; review and editing, M.B., L.A., G.A., M.P., P.M.; supervision, G.A., M.P., P.M.; funding acquisition, M.B., P.P.S., C.R., G.A., M.P., P.M. All authors have read and agreed to the published version of the manuscript.

Funding: This study was partly funded by the AGING Project for Department of Excellence at the Department of Translational Medicine (DIMET), Università del Piemonte Orientale, Novara, Italy.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. DeLuca, H.F. History of the discovery of vitamin D and its active metabolites. Bonekey Rep. 2014, 3, 479.
2. Blau, J.E.; Collins, M.T. The PTH-Vitamin D-FGF23 axis. Rev. Endocr. Metab. Disord. 2015, 16, 165–174.
3. Christakos, S.; Lieben, L.; Masuyama, R.; Carmeliet, G. Vitamin D endocrine system and the intestine. Bonekey Rep. 2014, 3, 496.
4. Demay, M.B.; Kiernan, M.S.; DeLuca, H.F.; Kronenberg, H.M. Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D3 receptor and mediate transcriptional repression in response to 1,25-dihydroxyvitamin D3. Proc. Natl. Acad. Sci. USA 1992, 89, 8097–8101.

5. Di Somma, C.; Scarano, E.; Barrea, L.; Zhukouskaya, V.V.; Savastano, S.; Mele, C.; Scacchi, M.; Aimaretti, G.; Colao, A.; Marzullo, P. Vitamin D and Neurological Diseases: An Endocrine Sci. 2017, 18, 2482.

6. Tahwai, Z.; Orolinova, N.; Joshua, I.G.; Bader, M.; Fletcher, E.C. Altered vascular reactivity in arterioles of chronic intermittent hypoxic rats. J. Appl. Physiol. 2001, 90, 2007–2013.

7. Talmor, Y.; Golan, E.; Bencherit, S.; Bernheim, J.; Klein, O.; Green, J.; Rashid, G. Calcitriol blunts the deleterious impact of advanced glycated end products on endothelial cells. Am. J. Physiol. Renal Physiol. 2008, 294, F1059–F1064.

8. Molinari, C.; Rizzi, M.; Squiralli, D.F.; Pittarelli, A.P.; Vacca, G.; Renò, F. 1a,25-Dihydroxycholecalciferol (Vitamin D3) induces NO-dependent endothelial cell proliferation and migration in a three-dimensional matrix. Cell Physiol. Biochem. 2013, 31, 815–822.

9. Li, Y.C.; Qiao, G.; Uskokovic, M.; Xiang, W.; Zheng, W.; Kong, J. Vitamin D: A negative endocrine regulator of the renin-angiotensin system and blood pressure. J. Steroid Biochem. Mol. Biol. 2004, 89–90, 387–392.

10. Bellan, M.; Guzzaloni, G.; Rinaldi, M.; Merlotti, E.; Ferrari, C.; Tagliaferri, A.; Pirisi, M.; Aimaretti, G.; Scacchi, M.; Marzullo, P. Altered glucose metabolism rather than naive type 2 diabetes mellitus (T2DM) is related to vitamin D status in severe obesity. Cardiovasc. Diabetol. 2014, 13, 57.

11. Grübler, M.R.; März, W.; Pilz, S.; Grammer, T.B.; Trummer, C.; Müllner, C.; Schett, G.; Pandis, M.; Verheyen, N.; Tomáschitz, A.; et al. Vitamin-D concentrations, cardiovascular risk and events—A review of epidemiological evidence. Rev. Endocr. Metab. Disord. 2017, 18, 259–272.

12. Caristia, S.; Filigheddu, N.; Barone-Adesi, F.; Sarro, A.; Testa, T.; Magnani, C.; Aimaretti, G.; Faggiano, F.; Marzullo, P. Vitamin D as a Biomarker of Ill Health among the Over-50s: A Systematic Review of Cohort Studies. Nutrients 2019, 11, 2384.

13. Novershtern, N.; Subramanian, A.; Lawton, L.N.; Mak, R.H.; Haining, W.N.; McConkey, M.E.; Habib, N.; Yosef, N.; Chang, C.Y.; Shay, T.; et al. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell 2011, 144, 296–309.

14. Gyetko, M.R.; Hsu, C.H.; Wilkinson, C.C.; Patel, S.; Young, E. Monocyte 1 alpha-hydroxylase regulation: Induction by inflammatory cytokines and suppression by dexamethasone and uremia toxin. J. Leukoc. Biol. 1993, 54, 17–22.

15. Gombart, A.F.; Borregaard, N.; Koefller, H.P. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J. 2005, 19, 1067–1077.

16. Wang, T.T.; Nestel, F.P.; Bourdeau, V.; Nagai, Y.; Wang, Q.; Liao, J.; Tavera-Mendoza, L.; Lin, R.; Hanahan, J.W.; Mader, S.; et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J. Immunol. 2004, 173, 2909–2912.

17. Sassi, F.; Tamone, C.; D’Amelio, P. Vitamin D: Nutrient, Hormone, and Immunomodulator. Nutrients 2018, 10, 1656.

18. Shin, D.M.; Yuk, J.M.; Lee, H.M.; Lee, S.H.; Son, J.W.; Harding, C.V.; Kim, J.M.; Modlin, R.L.; Jo, E.K. Mycobacterial lipoprotein activates autophagy via TLR2/1/CD14 and a functional vitamin D receptor signalling. Cell. Microbiol. 2010, 12, 1648–1665.

19. Sly, L.M.; Lopez, M.; Nauseef, W.M.; Reiner, N.E. 1alpha,25-Dihydroxyvitamin D3-induced monocyte antimycobacterial activity is regulated by phosphatidylinositol 3-kinase and mediated by the NADPH-dependent phagocyte oxidase. J. Biol. Chem. 2001, 276, 35482–35493.

20. Agraz-Cibrian, J.M.; Giraldo, D.M.; Urcuqui-Inchima, S. 1,25-Dihydroxyvitamin D3 induces formation of neutrophil extracellular trap-like structures and modulates the transcription of genes whose products are neutrophil extracellular trap-associated proteins: A pilot study. Steroids 2019, 141, 14–22.

21. Tokuda, N.; Levy, R.B. 1,25-dihydroxyvitamin D3 stimulates phagocytosis but suppresses HLA-DR and CD13 antigen expression in human mononuclear phagocytes. Proc. Soc. Exp. Biol. Med. 1996, 211, 244–250.

22. Xu, H.; Soruri, A.; Gieseler, R.K.H.; Peters, J.H. 1,25-Dihydroxyvitamin D3 exerts opposing effects to IL-4 on MHC class II antigen expression, accessory activity, and phagocytosis of human monocytes. Scand. J. Immunol. 1993, 38, 535–540.

23. Kreutz, M.; Andressen, R. Induction of human monocyte to macrophage maturation in vitro by 1,25-dihydroxyvitamin D3. Blood 1990, 76, 2457–2461.
24. Berer, A.; Stöckl, J.; Majdic, O.; Wagner, T.; Kollars, M.; Lechner, K.; Geissler, K.; Oehler, L. 1,25-Dihydroxyvitamin D(3) inhibits dendritic cell differentiation and maturation in vitro. Exp. Hematol. 2000, 28, 575–583.

25. Griffith, M.D.; Lutz, W.H.; Phan, V.A.; Bachman, L.A.; McKean, D.J.; Kumar, R. Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem. Biophys. Res. Commun. 2000, 270, 701–708.

26. Gauzi, M.C.; Purificato, C.; Donato, K.; Jin, Y.; Wang, L.; Daniel, K.C.; Maghazachi, A.A.; Belardelli, F.; Adorini, L.; Gessani, S. Suppressive effect of 1alpha,25-dihydroxyvitamin D3 on type I IFN-mediated monocyte differentiation into dendritic cells: Impairment of functional activities and chemotaxis. J. Immunol. 2005, 174, 270–276.

27. Zhang, Y.; Leung, D.Y.; Richers, B.N.; Liu, Y.; Remigio, L.K.; Riches, D.W.; Goleva, E. Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J. Immunol. 2012, 188, 2127–2135.

28. Rolf, L.; Muris, A.H.; Hupperts, R.; Damoiseaux, J. Illuminating vitamin D effects on B cells--the multiple sclerosis perspective. Immunology 2016, 147, 275–284.

29. Chen, S.; Sims, G.P.; Chen, X.X.; Gu, Y.Y.; Chen, S.; Lipsky, P.E. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J. Immunol. 2007, 179, 1634–1647.

30. Drozdenko, G.; Scheel, T.; Heine, G.; Baumgrass, R.; Worm, M. Impaired T cell activation and cytokine production by calcitriol-primed human B cells. Clin. Exp. Immunol. 2014, 178, 364–372.

31. Cippitelli, M.; Fionda, C.; Di Bona, D.; Di Rosa, F.; Lupo, A.; Piccoli, M.; Frati, L.; Santoni, A. Negative regulation of CD95 ligand gene expression by vitamin D3 in T lymphocytes. J. Immunol. 2002, 168, 1154–1166.

32. Xie, Z.; Chen, J.; Zheng, C.; Wu, J.; Cheng, Y.; Zhu, S.; Lin, C.; Cao, Q.; Zhu, J.; Jin, T. 1,25-dihydroxyvitamin D3 -induced dendritic cells suppress experimental autoimmune encephalomyelitis by increasing proportions of the regulatory lymphocytes and reducing T helper type 1 and type 17 cells. Immunology 2017, 152, 414–424.

33. Rigby, W.F.; Denome, S.; Fanger, M.W. Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA. J. Clin. Investig. 1987, 79, 1659–1664.

34. Colin, E.M.; Asmawidjaja, P.S.; van Hamburg, J.P.; Mus, A.M.C.; van Driel, M.; Hazes, J.M.W.; van Leeuwen, J.P.T.M., Lubberts, E. 1,25-dihydroxyvitamin D3 modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis. Arthritis Rheum. 2010, 62, 132–142.

35. Cantorna, M.T.; Woodward, W.D.; Hayes, C.E.; DeLuca, H.F. 1,25-dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-beta 1 and IL-4. J. Immunol. 1998, 160, 5314–5319.

36. Sloka, S.; Silva, C.; Wang, J.; Yong, V.W. Predominance of Th2 polarization by vitamin D through a STAT6-dependent mechanism. J. Neuroinflammation 2011, 8, 56.

37. Jeffery, L.E.; Wood, A.M.; Qureshi, O.S.; Hou, T.Z.; Gardner, D.; Briggs, Z.; Kaur, S.; Raza, K.; Sansom, D.M. Availability of 25-hydroxyvitamin D(3) to APCs controls the balance between regulatory and inflammatory T cell responses. J. Immunol. 2012, 189, 5155–5164.

38. Zhou, Q.; Qin, S.; Zhang, J.; Zhen, L.; Pen, Z.L.; Xing, T. 1,25(OH)2D3 induces regulatory T cell differentiation by influencing the VDR/PLC-γ1/TGF-β1/pathway. Mol. Immunol. 2017, 91, 156–164.

39. Zwerina, K.; Baum, W.; Axsman, R.; Heiland, G.R.; Distler, J.H.; Smolen, J.; Hayer, S.; Zwerina, J.; Schett, G. Vitamin D receptor regulates TNF-mediated arthritis. Ann. Rheum. Dis. 2011, 70, 1122–1129.

40. Tsuji, M.; Fuji, K.; Nakano, T.; Nishii, Y. 1 alpha-hydroxyvitamin D3 inhibits type II collagen-induced arthritis in rats. FEBS Lett. 1994, 337, 248–250.

41. Larsson, P.; Mattisson, L.; Klareskog, L.; Johnsson, C. A vitamin D analogue (MC 1288) has immunomodulatory properties and suppresses collagen-induced arthritis (CIA) without causing hypercalcemia. Clin. Exp. Immunol. 1998, 114, 277–283.

42. Moghaddami, M.; Mayrhofer, G.; Anderson, P.H.; Morris, H.A.; Van Der Hoek, M.; Cleland, L.G. Efficacy and mechanisms of action of vitamin D in experimental polyarthritis. Immunol. Cell Biol. 2012, 90, 168–177.

43. Neve, A.; Corrado, A.; Cantatore, F.P. Immunomodulatory effects of vitamin D in peripheral blood monocyte-derived macrophages from patients with rheumatoid arthritis. Clin. Exp. Med. 2014, 14, 275–283.

44. Harry, R.A.; Anderson, A.E.; Isaacs, J.D.; Hilkens, C.M. Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann. Rheum. Dis. 2010, 69, 2042–2050.
45. Stoop, J.N.; Harry, R.A.; von Delwig, A.; Isaacs, J.D.; Robinson, J.H.; Hilkens, C.M. Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses. *Arthritis Rheum.* 2010, 62, 3656–3665.

46. Zhou, L.; Wang, J.; Li, J.; Li, T.; Chen, Y.; June, R.R.; Zheng, S.G. 1,25-Dihydroxyvitamin D3 Ameliorates Collagen-Induced Arthritis via Suppression of Th17 Cells Through mIR-124 Mediated Inhibition of IL-6 Signaling. *Front. Immunol.* 2019, 10, 178.

47. Laragione, T.; Shah, A.; Gulkos, P.S. The vitamin D receptor regulates rheumatoid arthritis synovial fibroblast invasion and morphology. *Mol. Med.* 2012, 18, 194–200.

48. Gu, X.; Gu, B.; Lv, X.; Yu, Z.; Wang, R.; Zhou, X.; Qiao, W.; Mao, Z.; Zuo, G.; Li, Q.; et al. 25-dihydroxy-vitamin D3 with tumor necrosis factor-alpha protects against rheumatoid arthritis by promoting p53 acetylation-mediated apoptosis via Sirt1 in synoviocytes. *Cell Death Dis.* 2016, 7, e2423.

49. Sun, H.Q.; Yan, D.; Wang, Q.N.; Meng, H.Z.; Zhang, Y.Y.; Yin, L.X.; Yan, X.F.; Li, S.F. 1,25-Dihydroxyvitamin D3 attenuates disease severity and induces synoviocyte apoptosis in a concentration-dependent manner in rats with adjuvant-induced arthritis by inactivating the NF-kB signaling pathway. *J. Bone Miner. Metab.* 2019, 37, 430–440.

50. Wen, H.; Liu, Y.; Li, J.; Wei, D.; Liu, D.; Zhao, F. Inhibitory effect and mechanism of 1,25-dihydroxy vitamin D3 on RANKL expression in fibroblast-like synoviocytes and osteoclast-like cell formation induced by IL-22 in rheumatoid arthritis. *Clin. Exp. Rheumatol.* 2018, 36, 798–805.

51. Sainaghi, P.P.; Bellan, M.; Carda, S.; Cerutti, C.; Sola, D.; Nerviani, A.; Molinari, R.; Cisari, C.; Avanzi, G.C. Hypovitaminosis D and response to cholecalciferol supplementation in patients with autoimmune and non-autoimmune rheumatic diseases. *Rheumatol. Int.* 2012, 32, 3365–3372.

52. Kriegel, M.A.; Manson, J.E.; Costenbader, K.H. Does vitamin D affect risk of developing autoimmune disease? A systematic review. *Semin. Arthritis Rheum.* 2011, 40, 512–531.e8.

53. Merlino, L.A.; Curtis, J.; Mikuls, T.R.; Cerhan, J.R.; Criswell, L.A.; Saag, K.G.; Iowa Women’s Health Study. Vitamin D intake is inversely associated with rheumatoid arthritis: Results from the Iowa Women’s Health Study. *Arthritis Rheum.* 2004, 50, 72–77.

54. Lee, Y.H.; Bae, S.C. Vitamin D level in rheumatoid arthritis and its correlation with the disease activity: A meta-analysis. *Clin. Exp. Rheumatol.* 2016, 34, 827–833.

55. Cecchetti, S.; Tatar, Z.; Galan, P.; Pereira, B.; Lambert, C.; Mouterde, G.; Sutton, A.; Soubrier, M.; Dougdos, M. Prevalence of vitamin D deficiency in rheumatoid arthritis and association with disease activity and cardiovascular risk factors: Data from the COMEDRA study. *Clin. Exp. Rheumatol.* 2016, 34, 984–990.

56. Bellan, M.; Sainaghi, P.P.; Pirisi, M. Role of Vitamin D in Rheumatoid Arthritis. *Adv. Exp. Med. Biol.* 2017, 996, 155–168.

57. Bellan, M.; Pirisi, M.; Sainaghi, P.P. Osteoporosis in Rheumatoid Arthritis: Role of the vitamin D-parathyroid hormone system. *Rev. Bras. Reumatol.* 2015, 55, 256–263.

58. Bellan, M.; Andreoli, L.; Nerviani, A.; Piantoni, S.; Avanzi, G.C.; Loddo, D.; Hayden, E.; Pirisi, M.; Sainaghi, P.P. Is cholecalciferol a potential disease modifying anti-rheumatic drug for the management of rheumatoid arthritis? *Clin. Exp. Rheumatol.* 2019, in press.

59. Yesil, H.; Sungur, U.; Akdeniz, S.; Gurer, G.; Yalcın, B.; Dundar, U. Association between serum vitamin D levels and neuropathic pain in rheumatoid arthritis patients: A cross-sectional study. *Int. J. Rheum. Dis.* 2018, 21, 431–439.

60. Adami, G.; Rossini, M.; Bogliolo, L.; Cantatore, F.P.; Varenna, M.; Malavolta, N.; Del Puente, A.; Muratore, M.; Orsolini, G.; Gatti, D.; et al. An exploratory study on the role of vitamin D supplementation in improving pain and disease activity in rheumatoid arthritis. *Mod. Rheumatol.* 2019, 29, 1059–1062.

61. Chandrashekara, S.; Patted, A. Role of vitamin D supplementation in improving disease activity in rheumatoid arthritis: An exploratory study. *Int. J. Rheum. Dis.* 2017, 20, 825–831.

62. Brohult, J.; Jonsson, B. Effects of large doses of calciferol on patients with rheumatoid arthritis. A double-blind clinical trial. *Scand. J. Rheumatol.* 1973, 2, 173–176.

63. Fairney, A.; Straffen, A.M.; May, C.; Seifert, M.H. Vitamin D metabolites in synovial fluid. *Ann. Rheum. Dis.* 1987, 46, 370–374.

64. Sainaghi, P.P.; Bellan, M.; Nerviani, A.; Sola, D.; Molinari, R.; Cerutti, C.; Pirisi, M. Superiority of a high loading dose of cholecalciferol to correct hypovitaminosis D in patients with inflammatory/autoimmune rheumatic diseases. *J. Rheumatol.* 2013, 40, 166–172.

65. Sainaghi, P.P.; Bellan, M.; Antonini, G.; Bellomo, G.; Pirisi, M. Unsuppressed parathyroid hormone in patients with autoimmune/inflammatory rheumatic diseases: Implications for vitamin D supplementation. *Rheumatology* 2011, 50, 2290–2296.
66. Fernandes, S.; Etcheto, A.; van der Heijde, D.; Landewé, R.; van den Bosch, F.; Dougdados, M.; Moltó, A. Vitamin D status in spondyloarthritis: Results of the ASAS-COMOSPA international study. *Clin. Exp. Rheumatol.* 2018, 36, 210–214.

67. Petho, Z.; Kucser-Jakab, E.; Kalina, E.; Balogh, A.; Pusztai, A.; Gulyas, K.; Horvath, A.; Szekanecz, Z.; Bhattoa, H.P. Vitamin D status in men with psoriatic arthritis: A case-control study. *Osteoporos. Int.* 2015, 26, 1965–1970.

68. Orgaz-Molina, J.; Buendia-Eisman, A.; Arrabal-Polo, M.A.; Ruiz, J.C.; Arias-Santiago, S. Deficiency of serum concentration of 25-hydroxyvitamin D in psoriatic patients: A case-control study. *J. Am. Acad. Dermatol.* 2012, 67, 931–938.

69. Huckins, D.; Felson, D.T.; Holick, M. Treatment of psoriatic arthritis with oral 1,25-dihydroxyvitamin D3: A pilot study. *Arthritis Rheum.* 1990, 33, 1723–1727.

70. Gaal, J.; Lakos, G.; Szodoray, P.; Kiss, J.; Horváth, I.; Horkay, E.; Nagy, G.; Szegedi, A. Immunological and clinical effects of alphacalcidol in patients with psoriatic arthropathy: Results of an open, follow-up pilot study. *Acta Derm. Venereol.* 2009, 89, 140–144.

71. Cai, G.; Wang, L.; Fan, D.; Xin, L.; Liu, L.; Hu, Y.; Ding, N.; Xu, S.; Xia, G.; Jin, X.; et al. Vitamin D in ankylosing spondylitis: Review and meta-analysis. *Clin. Chim. Acta* 2015, 438, 316–322.

72. Zhao, S.; Duffield, S.; Moots, R.J.; Goodson, N.J. Systematic review of association between vitamin D levels and susceptibility and disease activity of ankylosing spondylitis. *Rheumatology* 2014, 53, 1595–1603.

73. Durmus, B.; Altay, Z.; Baysal, O.; Ersoy, Y. Does vitamin D affect disease severity in patients with ankylosing spondylitis? *Clin. Med. J.* 2012, 125, 2511–2515.

74. Zhao, S.Z.; Thong, D.; Duffield, S.; Goodson, N. Vitamin D Deficiency in Axial Spondyloarthritis is Associated with Higher Disease Activity. *Arch. Rheumatol.* 2017, 32, 209–215.

75. Klingberg, E.; Oleröd, G.; Hammarsten, O.; Forsblad-d’Elia, H. The vitamin D status in ankylosing spondylitis in relation to intestinal inflammation, disease activity, and bone health: A cross-sectional study. *Osteopores Int.* 2016, 27, 2027–2033.

76. Gula, Z.; Kopczyńska, A.; Harńska, K.; Słomski, M.; Nowakowski, J.; Kwaśny-Krochin, B.; Gąsowski, J.; Korkosz, M. Vitamin D serum concentration is not related to the activity of spondyloarthritis—Preliminary study. *Reumatologia* 2018, 56, 388–391.

77. Lemire, J.M.; Ince, A.; Takashima, M. 1,25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/l mice. *Autoimmunity* 1992, 12, 143–148.

78. Vaisberg, M.W.; Kaneno, R.; Franco, M.F.; Mendes, N.F.; Influence of cholecalciferol (vitamin D3) on the course of experimental systemic lupus erythematosus in F1 (NZBxW) mice. *J. Clin. Lab. Anal.* 2000, 14, 91–96.

79. Yan, L.; Wu, P.; Gao, D.M.; Hu, J.; Wang, Q.; Chen, N.F.; Tong, S.Q.; Rao, L.; Liu, J. The Impact of Vitamin D on Cognitive Dysfunction in Mice with Systemic Lupus Erythematosus. *Med. Sci. Monit.* 2019, 25, 4716–4722.

80. Correa Freitas, E.; Evelyn Karnopp, T.; de Souza Silva, J.M.; Cavalheiro do Espirito Santo, R.; da Rosa, T.H.; de Oliveira, M.S.; da Costa Gonçalves, F.; de Oliveira, F.H.; Guilherme Schaefer, P.; André Monticelio, O. Vitamin D supplementation ameliorates arthritis but does not alleviates renal injury in pristane-induced lupus model. *Autoimmunity 2019*, 52, 69–77.

81. Linker-Israeli, M.; Elstner, E.; Klimenberg, J.R.; Wallace, D.J.; Koeffler, H.P. Vitamin D (3) and its synthetic analogs inhibit the spontaneous in vitro immunoglobulin production by SLE-derived PBMC. *Clin. Immunol.* 2001, 99, 82–93.

82. Lerman, M.; Burnham, J.; Behrens, E. 1,25 Dihydroxyvitamin D3 limits monocyte maturation in lupus sera. *Lupus* 2011, 20, 749–753.

83. Ben-Zvi, I.; Aranow, C.; Mackay, M.; Stanevsky, A.; Kamen, D.L.; Marinescu, L.M.; Collins, C.E.; Gilkeson, G.S.; Diamond, B.; Hardin, J.A. The impact of vitamin D on dendritic cell function in patients with systemic lupus erythematosus. *PLoS ONE* 2010, 5, e9193.

84. Piantoni, S.; Andreoli, L.; Scarsi, M.; Zanola, A.; Dall’Ara, F.; Pizzorni, C.; Cutolo, M.; Airò, P.; Tincani, A. Phenotype modifications of T-cells and their shift toward a Th2 response in patients with systemic lupus erythematosus supplemented with different monthly regimens of vitamin D. *Lupus* 2015, 24, 490–498.

85. Terrier, B.; Derian, N.; Schoindre, Y.; Chaara, W.; Geri, G.; Zahr, N.; Mariampillai, K.; Rosenzwajg, M.; Carpentier, W.; Musset, L.; et al. Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation. *Arthritis Res. Ther.* 2012, 14, R221.

86. Pludowski, P.; Holick, M.F.; Pilz, S.; Wagner, C.L.; Hollis, B.W.; Grant, W.B.; Shoenfeld, Y.; Lerchbaum, E.; Llewellyn, D.J.; Kienreich, K.; et al. Vitamin D effects on musculoskeletal health, immunity,
autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality—a review of recent evidence. *Autoimmun. Rev.* **2013**, *12*, 976–989.

87. Stagi, S.; Rigante, D. Vitamin D and juvenile systemic lupus erythematosus: Lights, shadows and still unresolved issues. *Autoimmun. Rev.* **2018**, *17*, 290–300.

88. Islam, M.A.; Khandker, S.S.; Alam, S.S.; Kotyla, P.; Hassan, R. Vitamin D status in patients with systemic lupus erythematosus (SLE): A systematic review and meta-analysis. *Autoimmun. Rev.* **2019**, *18*, 102392.

89. Guan, S.Y.; Cai, H.Y.; Wang, P.; Lv, T.T.; Liu, L.N.; Mao, Y.M.; Zhao, C.N.; Wu, Q.; Dan, Y.L.; Sam, N.B.; et al. Association between circulating 25-hydroxyvitamin D and systemic lupus erythematosus: A systematic review and meta-analysis. *Int. J. Rheum. Dis.* **2019**, *22*, 1803–1813.

90. Wang, X.R.; Xiao, J.P.; Zhang, J.J.; Wu, Y.G. Decreased Serum/Plasma Vitamin D levels in SLE Patients: A Meta-Analysis. *Curr. Pharm. Des.* **2018**, *24*, 4466–4473.

91. Ritterhouse, L.L.; Crowe, S.R.; Niewold, T.B.; Kamen, D.L.; Dall’Era, M.; Massarotti, E.M.; Mackay, M.C.; Koumpouras, F.; Coca, A.; Dutta, C.; Kakati, S.; Barman, B.; Bora, K. Vitamin D status and its relationship with systemic lupus erythematosus. *Exp. Rheumatol.* **2019**, *7*, 917–929.

92. Gittoes, N.J. Vitamin D—What is normal according to latest research and how should we deal with it? *Clin. Med.* **2015**, *15*(Suppl. 6), s54–s57.

93. O’Leary, T.J.; Jones, G.; Yip, A.; Lohnes, D.; Cohanim, M.; Yendt, E.R.: The effects of chloroquine on serum 1, 25-dihydroxyvitamin D and calcium metabolism in sarcoidosis. *N. Engl. J. Med.* **1986**, *315*, 727–730.

94. Ruiz-Irastorza, G.; Egurbide, M.V.; Olivares, N.; Martinez-Berriotxoa, A.; Aguirre, C. Vitamin D deficiency in systemic lupus erythematosus: Prevalence, predictors and clinical consequences. *Rheumatology* **2008**, *47*, 920–923.

95. Toloza, S.; Cole, D.; Gladman, D.; Ibanez, D.; Urowitz, M. Vitamin D insufficiency in a large female SLE cohort. *Lupus* **2010**, *19*, 13–19.

96. Kamen, D.L. Vitamin D in lupus-new kid on the block? *Bull. NYU Hosp. Jt. Dis.* **2010**, *68*, 218–222.

97. Akeno, N.; Matsunuma, A.; Maeda, T.; Kawanishi, T.; Horii, N. Regulation of vitamin D-1alpha-hydroxylase and -24-hydroxy-lase expression by dexamethasone in mouse kidney. *J. Endocrinol.* **2000**, *164*, 339–348.

98. Sumethkul, K.; Boonyaratavej, S.; Kitiomuaypong, T.; Angthararuk, S.; Cheewasat, P.; Manadee, N.; Sumethkul, V. The predictive factors of low serum 25-hydroxyvitamin D and vitamin D deficiency in patients with systemic lupus erythematosus. *Rheumatol. Int.* **2013**, *33*, 1461–1467.

99. Yu, Q.; Qiao, Y.; Liu, D.; Liu, F.; Gao, C.; Duan, J.; Liang, L.; Di, X.; Yuan, Y.; Gao, Y.; et al. Vitamin D protects podocytes from autoantibodies induced injury in lupus nephritis by reducing aberrant autophagy. *Arthritis Res. Ther.* **2019**, *21*, 19.

100. Nguyen, M.H.; Bryant, K.; O’Neill, S.G. Vitamin D in SLE: A role in pathogenesis and fatigue? A review of the literature. *Lupus* **2018**, *27*, 2003–2011.

101. Sabio, J.M.; Vargas-Hitos, J.A.; Martínez-Bordonado, J.; Mediavilla-García, J.D. Association between non-dipper hypertension and vitamin D deficiency in women with systemic lupus erythematosus. *Clin. Exp. Rheumatol.* **2019**, *37*, 286–292.

102. Mak, A. The Impact of Vitamin D on the Immunopathophysiology, Disease Activity, and Extra-Musculoskeletal Manifestations of Systemic Lupus Erythematosus. *Int. J. Mol. Sci.* **2018**, *19*, 2355.

103. Hussein, H.A.; Daker, L.I.; Fouad, N.A.; Elamir, A.; Mohamed, S.R. Does Vitamin D Deficiency Contribute to Cognitive Dysfunction in Patients with Systemic Lupus Erythematosus? *Innove. Clin. Neurosci.* **2018**, *15*, 25–29.

104. Mok, C.C.; Bro, E.T.; Ho, L.Y.; Singh, R.J.; Jannetto, P.J. Serum 25-hydroxyvitamin D3 levels and flares of systemic lupus erythematosus: A longitudinal cohort analysis. *Clin. Rheumatol.* **2018**, *37*, 2685–2692.

105. Dutta, C.; Kakati, S.; Barman, B.; Bora, K. Vitamin D status and its relationship with systemic lupus erythematosus as a determinant and outcome of disease activity. *Horm. Mol. Biol. Clin. Investig.* **2019**, *38*, doi: 10.1515/hmbci-2018-0064.

106. Aranow, C.; Kamen, D.L.; Dall’Era, M.; Massarotti, E.M.; Mackay, M.C.; Koumpouras, F.; Coca, A.; Chatham, W.W.; Cloowse, M.E.; Cricione-Schreiber, L.G.; et al. Randomized, double-blind, placebo-controlled trial of the effect of vitamin D3 on the interferon signature in patients with systemic lupus erythematosus. *Arthritis Rheumatol.* **2015**, *67*, 1848–1857.

107. Lima, G.L.; Paupitz, J.; Aikawa, N.E.; Takayama, L.; Bonfa, E.; Pereira, R.M. Vitamin D supplementation in adolescents and young adults with juvenile systemic lupus erythematosus for improvement in disease activity and fatigue scores: A randomized, double-blind, placebo-controlled trial. *Arthritis Care Res.* **2016**, *68*, 91–98.
108. Rifa’I, A.; Kalim, H.; Kusworini, K.; Cesarius, S.W. Effect of vitamin D supplementation on disease activity (SLEDAl) and fatigue in Systemic Lupus Erythematosus patients with hipovitamin D: An open clinical trial. *Indones. j. Rheumatol.* 2016, 8, 32–37.

109. Petri, M.; Bello, K.J.; Fang, H.; Magder, L.S. Vitamin D in systemic lupus erythematosus: Modest association with disease activity and the urine protein-to-creatinine ratio. *Arthritis Rheum.* 2013, 65, 1865–1871.

110. Andreoli, L.; Dall’Ara, F.; Piantoni, S.; Zanola, A.; Piva, N.; Cutolo, M.; Tincani, A. A 24-month prospective study on the efficacy and safety of two different monthly regimens of vitamin D supplementation in pre-menopausal women with systemic lupus erythematosus. *Lupus* 2015, 24, 499–506.

111. Ruiz-Irastorza, G.; Gordo, S.; Olivares, N.; Egurbide, M.V.; Aguirre, C. Changes in vitamin D levels in patients with systemic lupus erythematosus: effects on fatigue, disease activity, and damage. *Arthritis Care Res.* 2010, 62, 1160–1165.

112. Karimzadeh, H.; Shirzadi, M.; Karimifar, M. The effect of vitamin D supplementation in disease activity of systemic lupus erythematosus patients with vitamin D deficiency: A randomized clinical trial. *J. Res. Med. Sci.* 2017, 22, 4.

113. Bultink, I.E.; Lems, W.F. Lupus and fractures. *Curr. Opin. Rheumatol.* 2016, 28, 426–432.

114. Edens, C.; Robinson, A.B. Systemic lupus erythematosus, bone health, and osteoporosis. *Curr. Opin. Endocrinol. Diabetes Obes.* 2015, 22, 422–431.

115. Roman, M.J.; Crown, M.K.; Lockshin, M.D.; Devereux, R.B.; Paget, S.A.; Sammaritano, L.; Levine, D.M.; Davis, A.; Salmon, J.E. *Arthritis Rheum.* 2007, 56, 3412–3419.

116. Mellor-Pita, S.; Tutor-Ureta, P.; Rosado, S.; Alkadi, K.; Granado, F.; Jimenez-Ortiz, C.; Castejon, R. Calcium and vitamin D supplement intake may increase arterial stiffness in systemic lupus erythematosus patients. *Clin. Rheumatol.* 2019, 38, 1177–1186.

117. Dall’Ara, F.; Cutolo, M.; Andreoli, L.; Tincani, A.; Paolino, S. Vitamin D and systemic lupus erythematosus: A review of immunological and clinical aspects. *Clin. Exp. Rheumatol.* 2018, 36, 153–162.

118. Hollis, B.W. Editorial: The determination of circulating 25- hydroxyvitamin D: No easy task. *J Clin Endocrinol. Metab.* 2004, 89, 3149–3151.

119. Klack, K.; Carvalho, J.F. High frequency of vitamin D insufficiency in primary antiphospholipid syndrome. *Jt. Bone Spine* 2010, 77, 489–490.

120. Andreoli, L.; Piantoni, S.; Dall’Ara, F.; Allegri, F.; Meroni, P.L.; Tincani, A. Vitamin D and antiphospholipid syndrome. *Lupus* 2012, 21, 736–740.

121. Riancho-Zarrabeitia, L.; Cubería, M.; Muñoz, P.; Lópe-Hoyos, M.; García-Canale, S.; García-Unzueta, M.; Hernández, J.L.; Martínez-Taboada, V.M. Vitamin D and antiphospholipid syndrome: A retrospective cohort study and meta-analysis. *Semin. Arthritis Rheum.* 2018, 47, 877–882.

122. Piantoni, S.; Andreoli, L.; Allegri, F.; Meroni, P.L.; Tincani, A. Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease. *Reumatismo* 2012, 64, 307–313.

123. García-Carrasco, M.; Jiménez-Herrera, E.A.; Gálvez-Romero, J.L.; Mendoza-Pinto, C.; Méndez-Martínez, S.; Etchebaray-Morales, J.; Munguía-Realpozo, P.; Vázquez de Lara-Cisneros, L.; Santa Cruz, F.J.; Cervera, R. The anti-thrombotic effects of vitamin D and their possible relationship with antiphospholipid syndrome. *Lupus* 2018, 27, 2181–2189.

124. Agmon-Levin, N.; Blank, M.; Zandman-Goddard, M.; Orbach, H.; Meroni, P.L.; Tincani, A.; Doria, A.; Cervera, R.; Miesbach, W.; Stojanovich, L.; et al. Vitamin D: An instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. *Ann. Rheum. Dis.* 2011, 70, 145–150.

125. Lindqvist, P.G.; Epstein, E.; Olsson, H. Does an active sun exposure habit lower the risk of venous thrombotic events? A D-lightful hypothesis. *J. Thromb. Haemost.* 2009, 7, 605–610.

126. Beer, T.M.; Venner, P.M.; Ryan, C.W.; Petrylak, D.P.; Chatta, G.; Dean Ruether, J.; Chi, K.N.; Curd, J.G.; DeLoughery, T.G. High dose calcitriol may reduce thrombosis in cancer patients. *Br. J. Haematol.* 2006, 135, 392–394.

127. Wu-Wong, J.R. Are vitamin D receptor activators useful for the treatment of thrombosis? *Curr. Opin. Investig. Drugs* 2009, 10, 919–927.

128. Jorde, R.; Sneve, M.; Torjesen, P.; Figenschau, Y.; Hansen, J.B. Parameters of the thrombogram are associated with serum 25-hydroxyvitamin D levels at baseline, but not affected during supplementation with vitamin D. *Thromb. Res.* 2010, 125, e210–e213.

129. Ota, K.; Dambaeva, S.; Han, A.R.; Beaman, K.; Gilman-Sachs, A.; Kwak-Kim, J. Vitamin D deficiency may be a risk factor for recurrent pregnancy losses by increasing cellular immunity and autoimmunity. *Hum. Reprod.* 2014, 29, 208–219.
Nutrients 2019, 12, 789

130. Barrera, D.; Avila, E.; Hernandez, G.; Halhali, A.; Biruete, B.; Larrea, F.; Diaz, L. Estradiol and progesterone synthesis in human placenta is stimulated by calcitriol. J. Steroid Biochem. Mol. Biol. 2007, 103, 529–532.

131. Diaz, L.; Noyola-Martinez, N.; Barrera, D.; Hernandez, G.; Avila, E.; Halhali, A.; Larrea, F. Calcitriol inhibits TNF-alpha-induced inflammatory cytokines in human trophoblasts. J. Reprod. Immunol. 2009, 81, 17–24.

132. Andreoli, L.; Bertias, G.K.; Agmon-Levin, N.; Brown, S.; Cervera, R.; Costedoat-Chalumeau, N.; Doria, A.; Fischer-Betz, R.; Forger, F.; Moraes-Fontes, M.F.; et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann. Rheum. Dis. 2017, 76, 476–485.

133. Eisenbarth, G.S. Type I diabetes mellitus. A chronic autoimmune disease. N. Engl. J. Med. 1986, 314, 1360–1368.

134. Atkinson, M.A.; Eisenbarth, G.S.; Michels, A.W. Type 1 diabetes. Lancet 2014, 383, 69–82.

135. Noble, J.A.; Erlich, H.A. Genetics of type 1 diabetes. Cold Spring Harb. Perspect. Med. 2012, 2, 1–15.

136. Paschou, S.A.; Papadopoulou-Marketou, N.; Chrousos, G.P.; Kanaka-Gantenbein, C. On type 1 diabetes mellitus pathogenesis. Endocr. Connect. 2018, 7, 38–46.

137. Norris, J.M.; Johnson, R.K.; Stene, L.C. Type 1 diabetes-early life origins and changing epidemiology. Lancet Diabetes Endocrinol. 2020, S2213–5858, 30412–30307.

138. Kahles, H.; Morahan, G.; Todd, J.A.; Badenhoop, K.; Type I Diabetes Genetics Consortium. Association analyses of the vitamin D receptor gene in 1654 families with type I diabetes. Genes Immun. 2009, 10 (Suppl 1), S60–S63.

139. Ban, Y.; Taniyama, M.; Yanagawa, T.; Yamada, S.; Maruyama, T.; Kasuga, A. Vitamin D receptor initiation codon polymorphism influences genetic susceptibility to type 1 diabetes mellitus in the Japanese population. BMC Med. Genet. 2001, 2, 7.

140. van Etten, E.; Verlinden, L.; Giulietti, A.; Ramos-Lopez, E.; Branisteantea, D.D.; Ferreira, G.B.; Overbergh, L.; Verstuyf, A.; Bouillon, R.; Roep, B.O.; et al. The vitamin D receptor gene FokI polymorphism: Functional impact on the immune system. Eur. J. Immunol. 2007, 37, 395–405.

141. Zhang, J.; Li, W.; Liu, J.; Wu, W.; Ouyang, H.; Zhang, Q.; Wang, Y.; Liu, L.; Yang, R.; Liu, X.; et al. Polymorphisms in the vitamin D receptor gene and type 1 diabetes mellitus risk: An update by meta-analysis. Mol. Cell. Endocrinol. 2012, 355, 135–142.

142. Mukhtar, M.; Batool, A.; Wajid, A.; Qayyum, I. Vitamin D Receptor Gene Polymorphisms Influence T1D Susceptibility among Pakistanis. Int. J. Genom. 2017, 2017, 4171254.

143. Ali, R.; Fawzy, I.; Mohsen, I.; Settin, A. Evaluation of vitamin D receptor gene polymorphisms (Fok-I and Bsm-I) in T1DM Saudi children. J. Clin. Lab. Anal. 2018, 32, e22397.

144. Kirac, D.; Dincer Yazan, C.; Gezmis, H.; Yaman, A.; Haklar, G.; Sirikci, O.; Altunok, E.C.; Deynoli, O. VDBP, VDR Mutations and Other Factors Related With Vitamin D Metabolism May Be Associated With Type 1 Diabetes Mellitus. J. Clin. Lab. Anal. 2018, 64, 11–16.

145. Tapia, G.; Márild, K.; Dahl, S.R.; Lund-Blix, N.A.; Viken, M.K.; Lie, B.A.; Njøstad, P.R.; Joner, G.; Skrivarhag, T.; Cohen, A.S.; et al. Maternal and Newborn Vitamin D-Binding Protein, Vitamin D Levels, Vitamin D Receptor Genotype, and Childhood Type 1 Diabetes. Diabetes Care 2019, 42, 553–559.

146. Habibian, N.; Amoli, M.M.; Abbasi, F.; Rabbani, A.; Alipour, A.; Sayarifard, F.; Rostami, P.; Dizaji, S.P.; Saadati, B.; Setoodeh, A. Role of vitamin D and vitamin D receptor gene polymorphisms on residual beta cell function in children with type I diabetes mellitus. Pharmaco. Rep. 2019, 71, 282–288.

147. Rasoul, M.A.; Haider, M.Z.; Al-Maldi, M.; Al-Kandari, H.; Dhaunsi, G.S. Relationship of four vitamin D receptor gene polymorphisms with type 1 diabetes mellitus susceptibility in Kuwaiti children. BMC Pediatr. 2019, 19, 71.

148. Ahmed, A.E.; Sakhr, H.M.; Hassan, M.H.; El-Amir, M.I.; Ameen, H.H. Vitamin D receptor rs7975232, rs731236 and rs1544410 single nucleotide polymorphisms, and 25-hydroxyvitamin D levels in Egyptian children with type 1 diabetes mellitus: Effect of vitamin D co-therapy. Diabetes Metab. Syndr. Obes. 2019, 12, 703–716.

149. Sahin, O.A.; Goksen, D.; Ozpinar, A.; Serdar, M.; Onay, H. Association of vitamin D receptor polymorphisms and type 1 diabetes susceptibility in children: A meta-analysis. Endocr. Connect. 2017, 6, 159–171.

150. Walden-Kirk, H.; Rondas, D.; Bugliani, M.; Korf, H.; Van Lommel, L.; Brusgaard, K.; Christesen, H.T.; Schuit, F.; Proost, P.; Masini, M.; et al. Discovery of molecular pathways mediating 1,25-dihydroxyvitamin D3 protection against cytokine-induced inflammation and damage of human and male mouse islets of Langerhans. Endocrinology 2014, 155, 736–747.
151. Zipitis, C.S.; Akobeng, A.K. Vitamin D supplementation in early childhood and risk of type 1 diabetes: A systematic review and meta-analysis. *Arch. Dis. Child.* 2008, 93, 512–517.

152. Moltchanova, E.V.; Schreier, N.; Lammi, N.; Karvonen, M. Seasonal variation of diagnosis of type 1 diabetes mellitus in children worldwide. *Diabet. Med.* 2009, 26, 673–678.

153. Cadario, F.; Prodromou, F.; Savastio, S.; Monzani, A.; Balafrej, A.; Bellomo, G.; Bona, G. Vitamin D status and type 1 diabetes in children: Evaluation according to latitude and skin color. *Minerva Pediatr.* 2015, 67, 263–267.

154. Xia, Y.; Xie, Z.; Huang, G.; Zhou, Z. Incidence and trend of type 1 diabetes and the underlying environmental determinants. *Diabetes Metab. Res. Rev.* 2019, 35, e3075.

155. Hyppönen, E, Lääärä, E, Reunanen, A, Järvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: A birth-cohort study. *Lancet* 2001, 358, 1500–1503.

156. Sørensen, I.M.; Joner, G.; Jenum, P.A.; Eskild, A.; Brunborg, C.; Torjesen, P.A.; Steene, L.C. Vitamin D-binding protein and 25-hydroxyvitamin D during pregnancy in mothers whose children later developed type 1 diabetes. *Diabetes Metab. Res. Rev.* 2016, 32, 883–890.

157. Peng, R.; Li, Y.; Li, G.; Li, Z.; Zhang, Y.; Li, Q.; Sun, C. Lower serum 25 (OH) D concentrations in type 1 diabetes: A meta-analysis. *Diabetes Res. Clin. Pract.* 2015, 108, e71–e75.

158. Liu, C.; Lu, M.; Xia, X.; Wang, J.; Wan, Y.; He, L.; Li, M. Correlation of serum vitamin D level with type 1 diabetes mellitus in children: A meta-analysis. *Nutr. Hosp.* 2015, 32, 1591–1594.

159. Shen, L.; Zhuang, Q.S.; Ji, H.F. Assessment of vitamin D levels in type 1 and type 2 diabetes patients: Results from metaanalysis. *Mol. Nutr. Food Res.* 2016, 60, 1059–1067.

160. Wierzbicka E, Szalecki M, Pludowski P, Jaworski M, Brzozowska A. Vitamin D status, body composition and glycemic control in Polish adolescents with type 1 diabetes. *Minerva Endocrinol.* 2016, 41, 445–455.

161. Al Sawah, S.; Compher, C.W.; Hanlon, A.L.; Lipman, T.H. 25-Hydroxyvitamin D and glycemic control: A cross-sectional study of children and adolescents with type 1 diabetes. *Diabetes Res. Clin. Pract.* 2016, 115, 54–59.

162. Rasoul, M.A.; Al-Mahdi, M.; Al-Kandari, H.; Dhaunsi, G.S.; Haider, M.Z. Low serum vitamin-D status is associated with high prevalence and early onset of type-1 diabetes mellitus in Kuwaiti children. *BMC Pediatr.* 2016, 16, 95.

163. Savastio, S.; Cadario, F.; Genoni, G.; Bellomo, G.; Bagnati, M.; Secco, G.; Picchi, R.; Giglione, E.; Bona, G. Vitamin D Deficiency and Glycemic Status in Children and Adolescents with Type 1 Diabetes Mellitus. *PLoS ONE* 2016, 11, e0162554.

164. Talaat, I.M.; Nasr, A.; Alsaloum, A.A.; Alghamdi, H.; Alswat, K.A.; Almalki, D.M.; Abushouk, A.; Saleh, A.M.; Allam, G. Association between type 1, type 2 cytokines, diabetic autoantibodies and 25-hydroxyvitamin D in children with type 1 diabetes. *J. Endocrinol. Invest.* 2016, 39, 1425–1434.

165. Ziaei-Kajbaf, T.; Aminzadeh, M.; Fatahinezhad, E.; Aletayeb, S.M. Vitamin D status in diabetic children and adolescents. *Diabetes Metab. Syndr.* 2018, 12, 849–852.

166. Jacobsen, R.; Thorsen, S.U.; Cohen, A.S.; Lundqvist, M.; Frederiksen, P.; Pocior, C.B.; Fyhrquist, F.; Thygesen, L.C.; Ascherio, A.; Svensson, J.; et al. Neonatal vitamin D status is not associated with later risk of type 1 diabetes: Results from two large Danish population-based studies. *Diabetologia* 2016, 59, 1871–1881.

167. Wood, J.R.; Connor, C.G.; Cheng, P.; Ruedy, K.J.; Tamborlane, W.V.; Klingensmith, G.; Schatz, D.; Gregg, B.; Cengiz, E.; Willi, S.; et al. Vitamin D status in youth with type 1 and type 2 diabetes enrolled in the Pediatric Diabetes Consortium (PDC) is not worse than in youth without diabetes. *Pediatr. Diabetes* 2016, 17, 584–591.

168. Thorsen, S.U.; Mårdil, K.; Olsen, S.F.; Holst, K.K.; Tapia, G.; Granström, C.; Halldorsson, T.I.; Cohen, A.S.; Haugen, M.; Lundqvist, M.; et al. Lack of Association Between Maternal or Neonatal Vitamin D Status and Risk of Childhood Type 1 Diabetes: A Scandinavian Case-Cohort Study. *Am. J. Epidemiol.* 2018, 187, 1174–1181.

169. Dogan, B.; Oner, C.; Feyzioglu, G.; Yoruk, N.; Oguz, A. Vitamin D status of Turkish type 1 diabetic patients. *Diabetes Metab. Syndr.* 2019, 13, 2037–2039.

170. Pitocchi, D.; Crini, A.; Di Stasio, E.; Manfrini, S.; Guglielmi, C.; Spera, S.; Anguissola, G.B.; Visalli, N.; Suraci, C.; Matteoli, M.C.; et al. The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI). *Diabet. Med.* 2006, 23, 920–923.

171. Papadimitriou, D.T.; Marakaki, C.; Fretzayas, A.; Nicolaidou, P.; Papadimitriou, A. Negativation of type 1 diabetes-associated autoantibodies to glutamic acid decarboxylase and insulin in children treated with oral calcitriol. *J. Diabetes* 2013, 5, 344–348.

172. Li, X.; Liao, L.; Yan, X.; Huang, G.; Lin, J.; Lei, M.; Wang, X.; Zhou, Z. Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes (LADA). *Diabetes/Met. Res. Rev.* 2009, 25, 411–416.
173. Walter, M.; Kaupper, T.; Adler, K.; Foerusch, J.; Bonifacio, E.; Ziegler, A.G. No effect of the 1alpha, 25-dihydroxyvitamin D3 on beta-cell residual function and insulin requirement in adults with new-onset type 1 diabetes. *Diabetes Care* 2010, 33, 1443–1448.

174. Gregoriou, E.; Mamais, I.; Tzanetakou, I.; Lavranos, G.; Chrysostomou, S. The Effects of Vitamin D Supplementation in Newly Diagnosed Type 1 Diabetes Patients: Systematic Review of Randomized Controlled Trials. *Rev. Diabet. Stud.* 2017, 14, 260–268.

175. Felicio, K.M.; de Souza, A.C.C.B.; Neto, J.F.A.; de Melo, F.T.C.; Carvalho, C.T.; Arbaje, T.P.; de Rider Brito, H.A.; Peixoto, A.S.; de Oliveira, A.F.; de Souza Resende, F.; et al. Glycemic Variability and Insulin Needs in Patients with Type 1 Diabetes Mellitus Supplemented with Vitamin D: A Pilot Study Using Continuous Glucose Monitoring System. *Curr. Diabetes Rev.* 2018, 14, 395–403.

176. McLeod, D.S.; Cooper, D.S. The incidence and prevalence of thyroid autoimmunity. *Endocrine* 2012, 42, 252–265.

177. Kim, D. The role of vitamin D in thyroid diseases. *Int. J. Mol. Sci.* 2017, 18, 1949.

178. Antonelli, A.; Ferrari, S.M.; Corrado, A.; Di Domenicantonio, A.; Fallahi, P. Autoimmune thyroid disorders. *Autoimmun. Rev.* 2015, 14, 174–180.

179. Muscogiuri, G.; Tirabassi, G.; Bizzaro, G.; Orto, F.; Paschou, S.A.; Balercia, G.; Shoenfeld, Y.; Colao, A. Vitamin D and thyroid disease: To D or not to D? *Eur. J. Clin. Nutr.* 2015, 69, 291–296.

180. Gallo, D.; Mortara, L.; Gariboldi, M.B.; Cattaneo, S.A.M.; Rosetti, S.; Gentile, L.; Noonan, D.M.; Premoli, P.; Cusini, C.; Tanda, M.L.; et al. Immunomodulatory effect of vitamin D and its potential role in the prevention and treatment of thyroid autoimmunity: A narrative review. *J. Endocrinol. Invest.* 2019, in press.

181. Fournier, C.; Gepner, P.; Sadouk, M.; Charreire, J. In vivo beneficial effects of cyclosporin A and 1,25-dihydroxyvitamin D3 on the induction of experimental autoimmune thyroiditis. *Clin. Immunol. Immunopathol* 1990, 4, 53–63.

182. Borgogni, E.; Sarchielli, E.; Sottlii, M.; Santarlasco, V.; Cosmi, L.; Gelmini, S.; Lombardi, A.; Cantini, G.; Perigil, G.; Luconi, M.; et al. Elocalcitol inhibits inflammatory responses in human thyroid cells and T cells. *Endocrinology* 2008, 149, 3626–3634.

183. Misharin, A.; Hewison, M.; Shen, C.R.; Lagishetty, V.; Aliesky, H.A.; Mizutani, Y.; Rapoport, B.; McLachlan, S.M. Vitamin D deficiency modulates Graves’ hyperthyroidism induced in BALB/c mice by thyrotropin receptor immunization. *Endocrinology* 2009, 50, 1051–1060.

184. Liu, S.; Xiong, F.; Liu, E.M.; Zhu, M.; Lei, P.Y. Effects of 1,25-dihydroxyvitamin D3 in rats with experimental autoimmune thyroiditis. *J. South. Med. Univ.* 2010, 30, 1573–1576.

185. Catneregli, P.; De Remigis, A.; Rose, N.R. Hashimoto thyroiditis: Clinical and diagnostic criteria. *Autoimmun. Rev.* 2014, 13, 391–397.

186. Goswami, R.; Marwaha, R.K.; Gupta, N.; Tandon, N.; Sreenivas, V.; Tomar, N.; Ray, D.; Kanwar, R.; Agarwal, R. Prevalence of vitamin D deficiency and its relationship with thyroid autoimmunity in Asian Indians: A community-based survey. *Br. J. Nutr.* 2009, 102, 382–386.

187. Camurcan, O.M.; Döger, E.; Bideci, A.; Celik, N.; Cinaz, P. Vitamin D status in children with Hashimoto thyroiditis. *J. Pediatr. Endocrinol. Metab.* 2012, 25, 467–470.

188. Shin, D.Y.; Kim, K.J.; Kim, D.; Hwang, S.; Lee, E.J. Low serum vitamin D is associated with anti-thyroid peroxidase antibody in autoimmune thyroiditis. *Yonsei Med. J.* 2014, 55, 476–481.

189. Unal, A.D.; Tarcin, O.; Parildar, H.; Cigerli, O.; Eroglu, H.; Demirag, N.G. Vitamin D deficiency is related to thyroid antibodies in autoimmune thyroiditis. *Cent. Eur. J. Immunol.* 2014, 39, 493–497.

190. Wang, X.; Zynat, J.; Guo, Y.; Osmian, R.; Tuhuti, A.; Zhao, H.; Abdunaimu, M.; Wang, H.; Jin, X.; Xing. S. Low serum vitamin D is associated with anti-thyroid-globulin antibody in female individuals. *Int. J. Endocrinol.* 2015, 2015, 285290.

191. ElRawy, H.A.; Ghamem, N.S.; Elsayed, N.M.; Ali, H.M.; Rashed, L.A.; Mansour, M.M. Study of Vitamin D Level and Vitamin D Receptor Polymorphism in Hypothyroid Egyptian Patients. *J. Thyroid Res.* 2019, 2019, 3583250.

192. Kim, C.Y.; Lee, Y.J.; Choi, J.H.; Lee, S.Y.; Lee, H.Y.; Jeong, D.H.; Choi, Y.J. The Association between Low Vitamin D Status and Autoimmune Thyroid Disease in Korean Premenopausal Women: The 6th Korea National Health and Nutrition Examination Survey, 2013–2014. *Korean J. Fam. Med.* 2019, 40, 323–328.

193. Tamer, G.; Arık, S.; Tamer, I.; Coksert, D. Relative vitamin D insufficiency in Hashimoto’s thyroiditis. *Thyroid* 2011, 21, 891–896.

194. Bozkurt, N.C.; Karbek, B.; Ucan, B.; Sahin, M.; Cakal, E.; Ozbek, M.; Delibasi, T. The association between severity of vitamin D deficiency and Hashimoto’s thyroiditis. *Endocr. Pract.* 2013, 19, 479–484.
195. Choi, Y.M.; Kim, W.G.; Kim, T.Y.; Bae, S.J.; Kim, H.K.; Jang, E.K.; Jeon, M.J.; Han, J.M.; Lee, S.H.; Baek, J.H.; et al. Low levels of serum vitamin D3 are associated with autoimmune thyroid disease in pre-menopausal women. *Thyroid* 2014, 24, 655–661.

196. Evliyaoglu, O.; Acar, M.; Ozcabi, B.; Erginöz, E.; Bucak, F.; Erkan, O.; Kucur, M. Vitamin D deficiency and Hashimoto's thyroiditis in children and adolescents: A critical vitamin D level for this association? *J. Clin. Res. Pediatr. Endocrinol.* 2015, 7, 128–133.

197. Kim, D. Low vitamin D status is associated with hypothyroid Hashimoto's thyroiditis. *Hormones* 2016, 15, 385–393.

198. Muscogiuri, G.; Mari, D.; Prolo, S.; Fatti, L.M.; Cantone, M.C.; Garagnani, P. 25 Hydroxyvitamin D deficiency and its relationship to autoimmune thyroid disease in the elderly. *Int. J. Environ. Res. Public Health* 2016, 13, 850.

199. Kim, M.; Song, E.; Oh, H.S.; Park, S.; Kwon, H.; Jeon, M.J.; Kim, W.G.; Kim, W.B.; Shong, Y.K.; Kim, T.Y. Vitamin D deficiency affects thyroid autoimmunity and dysfunction in iodine-replete area: Korea national health and nutrition examination survey. *Endocrine* 2017, 58, 332–339.

200. Gao, X.R.; Yu, Y.G. Meta-Analysis of the Association between Vitamin D Receptor Polymorphisms and the Risk of Autoimmune Thyroid Disease. *Int. J. Endocrinol.* 2018, 2018, 2846943.

201. Simsek, Y.; Cakir, I.; Yetmis, M.; Dizard, O.S.; Baspinar, O.; Gokay, F. Effects of vitamin D treatment on thyroid autoimmunity. *J. Res. Med. Sci.* 2016, 21, 85.

202. Chaudhary, S.; Dutta, D.; Kumar, M.; Saha, S.; Mondal, S.A.; Kumar, A.; Mukhopadhyay, S. Vitamin D supplementation reduces thyroid peroxidase antibody levels in patients with autoimmune thyroid disease: An open-labeled randomized controlled trial. *Indian J. Endocrinol. Metab.* 2016, 20, 391–398.

203. Krysiak, R.; Kowalcze, K.; Okopień, B. Selenomethionine potentiates the impact of vitamin D on thyroid autoimmunity in euthyroid women with Hashimoto's thyroiditis and low vitamin D status. *Pharmacol. Rep.* 2018, 71, 367–373.

204. Krysiak, R.; Szkróbka, W.; Okopień, B. The effect of vitamin D on thyroid autoimmunity in levothyroxine-treated women with Hashimoto's thyroiditis and normal vitamin D Status. *Exp. Clin. Endocrinol. Diabetes* 2017, 125, 229–233.

205. Chahardoli, R.; Saboor-Yaraghi, A.A.; Amouzegar, A.; Khalili, D.; Vakili, A.Z.; Azizi, F. Can supplementation with vitamin D modify thyroid autoantibodies (Anti-TPO Ab, Anti-Tg Ab) and thyroid profile (T3, T4, TSH) in Hashimoto's thyroiditis? A double blind, Randomized clinical trial. *Horm. Metab. Res. 2019*, 51, 296–301.

206. Menconi, F.; Marcocci, C.; Marino, M. Diagnosis and classification of Graves' disease. *Autoimmun. Rev.* 2014, 13, 398–402.

207. Cooper, G.S.; Stroehla, B.C. The epidemiology of autoimmune diseases. *Autoimmun. Rev.* 2003, 2, 119–125.

208. Wiersinga, W.M. Clinical relevance of environmental factors in the pathogenesis of autoimmune thyroid disease. *Endocrinol. Metab.* 2016, 31, 213–222.

209. Yasuda, T.; Okamoto, Y.; Hamada, N.; Miyashita, K.; Takahara, M.; Sakamoto, F.; Miyatsuka, T.; Kitamura, T.; Katakami, N.; Kawamori, D.; et al. Serum vitamin D levels are decreased in patients without remission of Graves' disease. *Endocrine* 2013, 43, 230–232.

210. Planck, T.; Shahida B, Malm J, Manjer, J. Vitamin D in Graves Disease: Levels, Correlation with Laboratory and Clinical Parameters, and Genetics. *Eur. Thyroid J.* 2018, 7, 27–33.

211. Mangaraj, S.; Choudhury, A.K.; Swain, B.M.; Sarangi, P.K.; Mohanty, B.K.; Baliahsinha, A.K. Evaluation of vitamin D status and its impact on thyroid related parameters in new onset Graves' disease- A cross-sectional observational study. *Indian J. Endocrinol. Metab.* 2019, 23, 35–39.

212. Xu, M.Y.; Cao, B.; Yin, J.; Wang, D.F.; Chen, K.L.; Lu, Q.B. Vitamin D and Graves' disease: A meta-analysis update. *Nutrients* 2015, 7, 3813–3827.

213. Cho, Y.Y.; Chung, Y.J. Vitamin D supplementation does not prevent the recurrence of Graves' disease. *Sci Rep.* 2020, 10, 16.

214. Zhou, H.; Xu, C.; Gu, M. Vitamin D receptor (VDR) gene polymorphisms and Graves' disease: A meta-analysis. *Clin. Endocrinol.* 2009, 70, 938–945.

215. Erichsen, M.M.; Lavås, K.; Fouger, K.J.; Svartberg, J.; Hauge, E.R.; Bollerslev, J.; Berg, J.P.; Mella, B.; Husebye, E.S. Normal overall mortality rate in Addison’s disease, but young patients are at risk of premature death. *Eur. J. Endocrinol.* 2009, 160, 233–237.

216. Meyer, G.; Neumann, K.; Badenhoop, K.; Lindner, R. Increasing prevalence of Addison's disease in German females: Health insurance data 2008-2012. *Eur. J. Endocrinol.* 2014, 170, 367–373.

217. Barthel, A.; Benker, G.; Berens, K.; Diederich, S.; Manfras, B.; Gruber, M.; Kanczkowski, W.; Kline, G.; Kamvissi-Lorenz, V.; Hahner, S.; et al. An Update on Addison’s Disease. *Exp. Clin. Endocrinol. Diabetes* 2019, 127, 165–175.
218. Bratland, E.; Husebye, E.S. Cellular immunity and immunopathology in autoimmune Addison’s disease. Mol. Cell. Endocrinol. 2011, 336, 180–190.

219. Kraus, A.U.; Penna-Martinez, M.; Meyer, G.; Badenhoop, K. Vitamin D effects on monocytes’ CCL-2, IL6 and CD14 transcription in Addison’s disease and HLA susceptibility. J. Steroid Biochem. Mol. Biol. 2018, 177, 53–58.

220. Pani, M.A.; Seissler, J.; Usadel, K.H.; Badenhoop, K. Vitamin D receptor genotype is associated with Addison’s disease. Eur. J. Endocrinol./Eur. Fed. Endocr. Soc. 2002, 147, 635–640.

221. Lopez, E.R.; Zwermann, O.; Segni, M.; Meyer, G.; Reinecke, M.; Seissler, J.; Herwig, J.; Usadel, K.H.; Badenhoop, K. A promoter polymorphism of the CYP27B1 gene is associated with Addison’s disease, Hashimoto’s thyroiditis, Graves’ disease, and type 1 diabetes mellitus in Germans. Eur. J. Endocrinol./Eur. Fed. Endocr. Soc 2004, 151, 193–197.

222. Jennings, C.E.; Owen, C.J.; Wilson, V.; Pearce, S.H. A haplotype of the CYP27B1 promoter is associated with autoimmune Addison’s disease but not with Graves’ disease in a UK population. J. Mol. Endocrinol. 2005, 34, 859–863.

223. Fichna, M.; Zarawek, M.; Januszkiewicz-Lewandowska, D.; Gryczynska, M.; Fichna, P.; Sowinski, J. Association of the CYP27B1 C(-1260)A polymorphism with autoimmune Addison’s disease. Exp. Clin. Endocrinol. Diabetes 2010, 118, 544–549.

224. Ramagopalana, S.V.; Goldacre, R.; Disanto, G.; Giovannoni, G.; Goldacre, M.J. Hospital admissions for vitamin D related conditions and subsequent immune-mediated disease: Record-linkage studies. BMC Med. 2013, 11, 171.

225. Pazderska, A.; Fichna, M.; Mitchell, A.L.; Napier, C.M.; Gan, E.; Ruchala, M.; Santibanez-Koref, M.; Pearce, S.H. Impact of Month of Birth on the Risk of Development of Autoimmune Addison’s Disease. J. Clin. Endocrinol. Metab. 2016, 101, 4214–4218.

226. Penna-Martinez, M.; Filmann, N.; Bogdanou, D.; Shoghi, F.; Huenecke, S.; Schubert, R.; Herrmann, E.; Koehl, U.; Husebye, E.S.; Badenhoop, K. High-dose vitamin D in Addison’s disease regulates T-cells and monocytes: A pilot trial. Nutrition 2018, 49, 66–73.

227. Cutolo, M. Autoimmune polyendocrine syndromes. Autoimmun. Rev. 2014, 13, 85–89.

228. Altieri, B.; Muscogiuri, G.; Barrea, L.; Mathieu, C.; Vallone, C.V.; Mascitelli, L.; Bizzaro, G.; Altieri, V.M.; Martinez, M.; Filmann, N.; Bogdanou, D.; Shoghi, F.; Huenecke, S.; Schubert, R.; Herrmann, E.; Koehl, U.; Husebye, E.S.; Badenhoop, K. High-dose vitamin D in Addison’s disease regulates T-cells and monocytes: A pilot study. Nutrition 2018, 49, 66–73.

229. Husebye, E.S.; Anderson, M.S.; Kämpe, O. Autoimmune Polyendocrine Syndromes. N. Engl. J. Med. 2018, 378, 1132–1141.

230. Bellastella, G.; Maiorino, M.I.; Petrizzo, M.; De Bellis, A.; Capuano, A.; Esposito, K.; Giugliano, D. Vitamin D and autoimmunity: What happens in autoimmune polyendocrine syndromes? J. Endocrinol. Invest. 2015, 38, 629–633.

231. Lohse, A.W.; Chazouillères, O.; Dalekos, G.; Drenth, J.; Heneghan, M.; Hofer, H.; Lammert, F.; Lenzi, M. EASL Clinical Practice Guidelines: Autoimmune hepatitis, J. Hep. 2015, 63, 971–1004.

232. Hirschfield, G.M.; Beuers, U.; Corpechot, C.; Invernizzi, P.; Jones, D.; Marzioni, M.; Schramm, C. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J. Hepatol. 2017, 67, 145–172.

233. Jepsen, P.; Grønbæk, L.; Vilstrup, H. Worldwide Incidence of Autoimmune Liver Disease. Dig. Dis. 2015, 33 (Suppl 2), 2–12.

234. Hirschfield, G.M.; Karlsen, T.H.; Lindor, K.D.; Adams, D.H. Primary sclerosing cholangitis. Lancet 2013, 382, 1587–1599.

235. Baran, D.T.; Milne, M.L. 1,25Dihydroxyvitamin D increases hepatocyte cytosolic calcium levels. A potential regulator of vitamin D-25-hydroxylase. J. Clin. Investig. 1986, 77, 1622–1626.

236. Rixon, R.H.; Isaacs, R.J.; Whitfield, J.F. Control of DNA polymerase-alpha activity in regenerating rat liver by calcium and 1 alpha,25(OH)2D3. J. Cell. Physiol. 1989, 139, 354–360.

237. Drocourt, L.; Ourlin, J.C.; Pascussi, J.M.; Maurel, P.; Vilarem, M.J. Expression of CYP3A4, CYP2D6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J. Biol. Chem. 2002, 277, 25125–25132.

238. Lin, C.J.; Dardis, A.; Wijesuriya, S.D.; Abdullah, M.A.; Casella, S.J.; Miller, W.L. Lack of mutations in CYP2D6 and CYP2C9 in patients with apparent deficiency of vitamin D 25-hydroxylase. Mol. Genet. Metab. 2003, 80, 469–472.

239. Sutti, S.; Rigamonti, C.; Vidali, M.; Albano, E. CYP2E1 autoantibodies in liver diseases. Redox. Biol. 2014, 3, 72–78.

240. Lapierre, P.; Djilali-Saia, I.; Vitozzi, S.; Alvarez, F. A murine model of type 2 autoimmune hepatitis: Xenoinmunization with human antigens. Hepatology 2004, 39, 1066–1074.
241. Luong, K.V.; Nguyen, L.T. The role of vitamin D in autoimmune hepatitis. J. Clin. Med. Res. 2013, 5, 407–415.

242. Hu, X.D.; Jiang, S.L.; Liu, C.H.; Hu, Y.Y.; Liu, C.; Sun, M.Y.; Chen, G.F., Liu, P. Preventive effects of 1,25-(OH)2VD3 against ConA-induced mouse hepatitis through promoting vitamin D receptor gene expression. Acta Pharmacol. Sin. 2010, 31, 703–708.

243. Chen, E.Q.; Shi, Y.; Tang, H. New insight of vitamin D in chronic liver diseases. Hepatobiliary Pancreat. Dis. Int. 2014, 13, 580–585.

244. Czaja, A.J.; Montano-Loza, A.J. Evolving Role of Vitamin D in Immune-Mediated Disease and Its Implications in Autoimmune Hepatitis. Dig. Dis. Sci. 2019, 64, 324–344.

245. Bachelet, M.; Bader, C.; Merlot, A.M.; Laborde, K.; Snarska, J.; Ulmann, A. Cellular utilization of cytosolic NADPH in kidney and liver cells from rats fed a normal or a vitamin D-deficient diet. Cell Biochem. Funct. 1983, 1, 25–29.

246. Kumar, V. NKT-cell subsets: Promoters and protectors in inflammatory liver disease. J. Hepatol. 2013, 59, 618–620.

247. Lan, P.; Fan, Y.; Zhao, Y.; Lou, X.; Monsour, H.P.; Zhang, X.; Choi, Y.; Dou, Y.; Ishii, N.; Ghobrial, R.M.; et al. TNF superfamily receptorOX40 triggers invariant NKT cell pyroptosis and liver injury. J. Clin. Investig. 2017, 127, 2222–2234.

248. Smyk, D.S.; Mavropoulos, A.; Mieli-Vergani, G.; Vergani, D.; Lenzi, M.; Bogdanos, D.P. The Role of Invariant NKT in Autoimmune Liver Disease: Can Vitamin D Act as an Immunomodulator? Can. J. Gastroenterol. Hepatol. 2018, 2018, 81937.

249. Yu, S.; Cantorna, M.T. Epigenetic reduction in invariant NKT cells following in utero vitamin D deficiency in mice. J. Immunol. 2011, 186, 1384–1390.

250. Bhalla, A.K.; Amento, E.P.; Clemens, T.L.; Holick, M.F.; Krane, S.M. Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: Presence in monocytes and induction in T lymphocytes following activation. J. Clin. Endocrinol. Metab. 1983, 57, 1308–1310.

251. Gascon-Barré, M.; Demers, C.; Mirshahi, A.; Néron, S.; Zalzal, S.; Nanci, A. The normal liver harbors the vitamin D nuclear receptor in nonparenchymal and biliary epithelial cells. Hepatology 2003, 37, 1034–1042.

252. Ding, N.; Yu, R.T.; Subramaniam, N.; Sherman, M.H.; Wilson, C.; Rao, R.; Leblanc, M.; Coulter, S.; He, M.; Scott, C.; et al. A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response. Cell 2013, 153, 601–613.

253. Furrincieli, D.; Zúñiga, S.; Rey, C.; Wendum, D.; Lasnier, E.; Rainteau, D.; Braescu, T.; Falguières, T.; Boissan, M.; Cadoret, A.; et al. Vitamin D nuclear receptor deficiency promotes cholestatic liver injury by disruption of biliary epithelial cell junctions in mice. Hepatology 2013, 58, 1401–1412.

254. Ogura, M.; Nishida, S.; Ishizawa, M.; Sakurai, K.; Shimizu, M.; Matsu, S.; Amano, S.; Uno, S.; Makishima, M. Vitamin D3 modulates the expression of bile acid regulatory genes and represses inflammation in bile duct-ligated mice. J. Pharmacol. Exp. Ther. 2009, 328, 564–570.

255. Zhang, Y.; Leung, D.Y.; Goleva, E. Vitamin D enhances glucocorticoid action in human monocytes: Involvement of granulocyte-macrophage colony-stimulating factor and mediator complex subunit 14. J. Biol. Chem. 2013, 288, 14544–14553.

256. De Bosscher, K.; Vanden Berghe, W.; Haegeman, G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: Molecular mechanisms for gene repression. Endocr. Rev. 2003, 24, 488–522.

257. Abramovitch, S.; Dahan-Bachar, L.; Sharvit, E.; Weisman, Y.; Ben Tov, A.; Brazowski, E.; Reif, S. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut 2011, 60, 1728–1737.

258. Lee, U.E.; Friedman, S.L. Mechanisms of hepatic fibrogenesis. Best Pract. Res. Clin. Gastroenterol. 2011, 25, 195–206.

259. Abramovitch, S.; Sharvit, E.; Weisman, Y.; Bentov, A.; Brazowski, E.; Cohen, G.; Volovelsky, O.; Reif, S. Vitamin D inhibits development of liver fibrosis in an animal model but cannot ameliorate established cirrhosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2015, 308, G112–G120.

260. Potter, J.J.; Liu, X.; Koteish, A.; Mezey, E. 1,25-dihydroxyvitamin D3 and its nuclear receptor repress human α1(I) collagen expression and type I collagen formation. Liver Int. 2013, 33, 677–686.

261. Artaza, J.N.; Norris, K.C. Vitamin D reduces the expression of collagen and key profibrotic factors by inducing an antifibrotic phenotype in mesenchymal multipotent cells. J. Endocrinol. 2009, 200, 207–221.

262. Liu, Y.; Liu, H.; Meyer, C.; Li, J.; Nadalin, S.; Königsrainer, A.; Weng, H.; Dooley, S.; ten Dijke, P. Transforming growth factor-β (TGF-β)-mediated connective tissue growth factor (CTGF) expression in hepatic stellate cells requires Stat3 signaling activation. J. Biol. Chem. 2013, 288, 30708–30719.
263. Wang, L.; Yuan, T.; Du, G.; Zhao, Q.; Ma, L.; Zhu, J. The impact of 1,25-dihydroxyvitamin D3 on the expression of connective tissue growth factor and transforming growth factor-β1 in the myocardium of rats with diabetes. *Diabetes Res. Clin. Pract.* 2014, 104, 226–233.
264. Honasawek, S.; Udomsinprasert, W.; Chirathaworn, C.; Anomasiri, W.; Vejchapipat, P.; Poovorawan, Y. Correlation of connective tissue growth factor with liver stiffness measured by transient elastography in biliary atresia. *Hepatol. Res.* 2013, 43, 795–800.
265. Hochrath, K.; Stokes, C.S.; Geisel, J.; Pollheimer, M.J.; Fickert, P.; Dooley, S.; Lammert, F. Vitamin D modulates biliary fibrosis in ABCB4-deficient mice. *Hepatol. Int.* 2014, 8, 443–452.
266. Ebadi, M.; Bhanji, R.A.; Mazurak, V.C.; Lytvyak, E.; Mason, A.; Czaja, A.J.; Montano-Loza, A.J. Severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis. *Aliment. Pharmacol. Ther.* 2019, 49, 173–182.
267. Agmon-Levin, N.; Kopilov, R.; Selmi, C.; Nussinovitch, U.; Sánchez-Castañón, M.; López-Hoyos, M.; Amital, H.; Kivity, S.; Gershwin, E.M.; Shoenfeld, Y. Vitamin D in primary biliary cirrhosis, a plausible marker of advanced disease. *Immunol. Res.* 2015, 61, 141–146.
268. Kempinska-Podhorodecka, A.; Milkiewicz, M.; Jablonski, D.; Milkiewicz, P.; Wunsch, E. Apal polymorphism of vitamin D receptor affects health-related quality of life in patients with primary sclerosing cholangitis. *PloS ONE* 2017, 12, e0176264.
269. Stokes, C.S.; Krawczyk, M.; Reichel, C.; Lammert, F.; Grünhage, F. Vitamin D deficiency is associated with mortality in patients with advanced liver cirrhosis. *Eur. J. Clin. Investig.* 2014, 44, 176–183.
270. Efe, C.; Kav, T.; Aydin, C.; Cengiz, M.; Imga, N.N.; Purnak, T.; Smyk, D.S.; Torgutalp, M.; Turhan, T.; Ozenirler, S.; et al. Low serum vitamin D levels are associated with severe histological features and poor response to therapy in patients with autoimmune hepatitis. *Dig. Dis. Sci.* 2014, 59, 3035–3042.
271. Guo, G.Y.; Shi, Y.Q.; Wang, L.; Ren, X.; Han, Z.Y.; Guo, C.C.; Cui, L.N.; Wang, J.B.; Zhu, J.; Wang, N.; Zhang, J.; et al. Serum vitamin D level is associated with disease severity and response to ursodeoxycholic acid in primary biliary cirrhosis. *Aliment. Pharmacol. Ther.* 2015, 42, 221–230.
272. Vogel, A.; Strassburg, C.P.; Manns, M.P. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. *Hepatology* 2002, 35, 126–131.
273. Fan, L.; Tu, X.; Zhu, Y.; Zhou, L.; Pfeiffer, T.; Feltens, R.; Stoecker, W.; Zhong, R. Genetic association of vitamin D receptor polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. *J. Gastroenterol. Hepatol.* 2005, 20, 249–255.
274. Springer, J.E.; Cole, D.E.; Rubin, L.A.; Cauch-Dudek, K.; Harewood, L.; Evrovski, J.; Peltekova, V.D.; Heathcote, E.J. Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. *Gastroenterology* 2000, 118, 145–151.
275. Kempinska-Podhorodecka, A.; Milkiewicz, M.; Wasik, U.; Ligocka, J.; Zawadzki, M.; Krawczyk, M.; Milkiewicz, P. Decreased Expression of Vitamin D Receptor Affects an Immune Response in Primary Biliary Cholangitis via the VDR-miRNA155-SOCS1 Pathway. *Int. J. Mol. Sci.* 2017, 18, 289.
276. Czaja, A.J. Epigenetic changes and their implications in autoimmune hepatitis. *Eur. J. Clin. Investig.* 2018, 48, doi: 10.1111/eci.12899.
277. Fisher, L.; Fisher, A. Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease. *Clin. Gastroenterol. Hepatol.* 2007, 5, 513–520.
278. Bjelakovic, G.; Nikolova, D.; Bjelakovic, M.; Gluud, C. Vitamin D supplementation for chronic liver diseases in adults. *Cochrane Database Syst. Rev.* 2017, 11, CD011564.